CN1896088A - C-aryl glucoside sglt2 inhibitors - Google Patents

Abstract

SGLT2 inhibiting compounds are provided having formula (I) where R<1>, R<2>, and R<2a> are independently hydrogen, OH, OR<5>, lower alkyl, CF3, OCHF2, OCF3, SR<5i> or halogen, or two of R<1>, R<2> and R<2a> together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R<3> and R<4> are independently hydrogen, OH, OR<5a>, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, -OCHF2, -OCF3, halogen, -CN, -CO2R<5b>, -CO2H, -COR<6b>, -CH(OH)R<6c>, -CH(OR<5h>)R<6d>, -CONR<6>R<6a>, -NHCOR<5c>, -NHSO2R<5d>, -NHSO2Aryl, Aryl, -SR<5e>, -SOR<5f>, SO2R<5g>, SO2Aryl, or a five, six or seven membered heterocycle, or R<3> and R<4> together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R<5>, R<5a>, R<5b>, R<5c>, R<5d>, R<5e>, R<5f>, R<5g>, R<5h>, and R<5I> are independently lower alkyl; R<6>, R<6a>, R<6b>, R<6c> and R<6d> are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R<6> and R<6a> together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle; A is O, S, NH, or (CH2)n where n is 0 - 3. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

Description

The C-aryl glucoside SGL T 2 inhibitors

The application be that October 2, application number in 2000 are 00816741.9 the applying date, name is called the dividing an application of patent application of " C-aryl glucoside SGL T 2 inhibitors ".

Invention field

The present invention relates to the C-aryl glucoside, they are the inhibitor of the sodium dependent glucose translocator (SGLT2) found in intestines and kidney, and relate to independent use C-aryl glucoside or with a kind of, the antidiabetic medicine of two or more other types and/or a kind of, the therapeutical agent of two or more other types such as hypolipidemic (hypolipidemic agents) drug combination treatment diabetes, especially type ii diabetes, and hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome, diabetic complication, the method of atherosclerosis and relative disease.

Background of invention

Nearly 100,000,000 people in the whole world suffer from type ii diabetes (NIDDM), it is characterized in that because of excessive hepatic glucose produce and the periphery insulin resistance due to hyperglycemia, but its basic reason it be unclear that.Hyperglycemia is considered to form the primary hazard factor of diabetic complication, and may be impaired directly related with the insulin secretion that sees NIDDM in late period.Can expect that the normalizing of the blood sugar among the NIDDM patient will be improved the effect of Regular Insulin, and the development of payment diabetic complication.The inhibitor of expectation sodium-dependent glucose translocator SGLT2 will help to make plasma glucose levels normalizing by the drainage that increases glucose in kidney, perhaps also have the normalizing of body weight.

Need simultaneously to develop new, safe and orally active antidiabetic medicine,, comprise sulfonylurea, thiazolidinedione, N1,N1-Dimethylbiguanide and Regular Insulin, and avoid the potential side effect relevant with using these other medicines to replenish existing therapy.

Hyperglycemia is the sign of type ii diabetes (NIDDM); In diabetes, the Sustainable Control of plasma glucose levels can be offseted the development and the β cellular degeneration of the diabetic complication that sees the diabetes in late period.Plasma glucose filters in the renal glomerulus of kidney usually and is initiatively heavily absorbed at proximal tubule.SGLT2 seemingly is responsible for the main translocator of the reuptake of this position glucose.SGLT specific inhibitor phlorizin or closely-related analogue suppress this reuptake process of the rodent and the dog of diabetes by the drainage (but not having hypoglycemic side effect) that promotes glucose, cause the normalizing of plasma glucose levels.Existing report, with the SGLT2 inhibitor Zucker diabetes rat is carried out (6 months) treatment for a long time, can improve the reaction of Regular Insulin to glucemia, improve the susceptibility of Regular Insulin, and postpone ephrosis and the neuropathic morbidity of these animals, and no detectable pathology change and do not have a electrolyte imbalance in the blood plasma in kidney.In the diabetic subject, the selectivity of SGLT2 suppresses to be expected to make plasma glucose normalizing by increasing the drainage of glucose in urine, increases the susceptibility of Regular Insulin thus, and postpones the development of diabetic complication.

In kidney, 90% glucose reuptake betides in the epithelial cell of the preceding S1 sections of renal cortex proximal tubule, and SGLT2 may be a main translocator of being responsible for this reuptake.SGLT2 is 672 amino acid proteins that contain 14 transmembrane segments, and it mainly is expressed in the preceding S1 sections of kidney proximal tubule.The specificity of substrate, sodium dependency, and the characteristic of the heavy body of the positioning action of SGLT2 and people's renal cortex kidney proximal tubule of before having summarized, low-affinity, sodium-dependent glucose translocator is consistent.In addition, crossbred is exhausted the research prompting, and SGLT2 is the main Na in the proximal tubule S1 sections ⁺/ glucose cotransporter is because all sodium-dependent glucose transport activity that in fact is encoded in from the renocortical mRNA of rat is subjected to the inhibition to the specific antisense oligonucleotide of rat SGLT2.SGLT2 is the familial glycosuria of some type, and a kind of its middle kidney glucose heavily absorbs the candidate gene of impaired in various degree genetic abnormality.Do not have as yet in Yan Jiu these syndromes on a kind of SGLT2 locus of mapping in karyomit(e) 16 up to now.Yet the research of the rodent SGLTs of high homology is pointed out strongly, and SGLT2 is the main kidney sodium-dependency translocator of glucose, and points out the glycosuria locus coding SGLT2 that has mapped conditioning agent.The inhibition of expectation SGLT2 will be drained the level that reduces plasma glucose by the glucose that increases the diabetic subject.

SGLT1, another kind of sodium-dependent glucose cotransporter (amino acid levels of itself and SGLT2 has 60% identity) is expressed in small intestine and the S3 sections of kidney proximal tubule than far-end.Although their sequence is similar, people SGLT1 and SGLT2 are still on the biological chemistry diacritic.For SGLT1, Na ⁺The mol ratio of glucose to transhipment is 2: 1, and for SGLT2, mol ratio is 1: 1.For SGLT1 and SGLT2, its Na ⁺Km be respectively 32 and 250-300mM.Km value for the picked-up of the glucose of SGLT1 and SGLT2 and nonmetabolizable glucalogue Alpha-Methyl-D-glucopyranoside (AMG) is similar, promptly for SGLT1 and SGLT2 translocator, be respectively 0.8 and 1.6mM (glucose) and 0.4 and 1.6mM (AMG).Yet to difference really aspect the specificity of the sugar as the substrate of semi-lactosi, semi-lactosi only is the substrate of SGLT1 to these two kinds of translocators at them.

Give phlorizin, the active specific inhibitor of a kind of SGLT, at several diabetes rodent models with in a dog diabetes model, by promoting the drainage of glucose in the body, plasma glucose after reducing fasting and taking food, increase the utilization of glucose and do not have hypoglycemic side effect, the evidence of breaking with the conventional idea is provided.When the treatment of the phlorizin that reached for 2 weeks, do not observe morphologic detrimental action to plasma ion balance, renal function or kidney.In addition, when giving the intact animal phlorizin,, do not observe hypoglycemia or other detrimental actions no matter whether have glycosuria.The kidney SGLTs inhibitor (Tanabe Seiyaku) that has report to give 6 months periods can improve the plasma glucose of fasting and feed in fat NIDDM rat model, promote secretion of insulin and utilization, under the situation of the side effect of no hypoglycemia or kidney, offset ephrosis and neuropathic development.

Phlorizin itself is unobtrusive as oral pharmaceutical, because it is a kind of nonspecific SGLT1/SGLT2 inhibitor that is hydrolyzed to its aglycone Phloretin in enteron aisle, it is the inhibitor of effective facilitation glucose transport.The concurrent restraining effect of the glucose transporter of facilitation (GLUTs) is unwanted, because expect the hypoglycemia that such inhibitor will increase the weight of the resistance of periphery Regular Insulin and inspire central nervous system.Suppress SGLT1 and also can have serious negative consequence, (GGM) is illustrated as hereditary syndrome glucose/semi-lactosi malabsorption, wherein the sudden change of SGLT1 cotransporter causes that the glucose uptake of small intestine is impaired, and the diarrhoea and the dehydration that threaten life.Biological chemistry difference between SGLT2 and the SGLT1, and the sequence difference degree between them make and can identify optionally SGLT2 inhibitor.

Familial glycosuria syndrome is enteron aisle glucose transport wherein, and other ions and amino acid kidney are transported normal disease.As if as if familial glycosuria patient develops into usually has the normal plasma glucose level, and do not suffer from the serious healthy defective as their disease sequela, although the excretory glucose level is quite high sometimes (110-114g/ day).Main manifest symptom among these patients comprises voracity, diuresis and polydipsia, and kidney is seemingly normal on 26S Proteasome Structure and Function.Therefore, as if from obtainable evidence up to now, kidney has long-term negative test minimum in different normal individuals to the defective of the reuptake of glucose.

The O-aryl glucoside SGL T 2 inhibitors that is used for the treatment of diabetes is disclosed below with reference to document.

EP 598359A1 (also being JP 035988) (Tanabe Seiyaku) discloses following structure ACompound

Below EP 0850948A1 discloses BCompounds

JP 09188625A has expanded structure B, to comprise wherein R ³For H and wherein 5 yuan of rings be saturated BCompound and thionaphthene (O=S) and indenes (O=CH ₂) counterpart.

JP 09124685A has expanded R ³The structure of=H B, comprising an acylations C6 hydroxy derivative, wherein said acyl group is the phenylformic acid that replaces or pyridyl carboxylic acid or the urethane that generated by corresponding phenol.

JP 09124684 discloses structure BDerivative

EP 773226-A1 discloses structure BDerivative

JP 08027006-A discloses structure ADerivative, as if wherein the various combinations of glucose hydroxyl are by acylations and similar with EP 598359A1.

As if EP 684254-A1 comprised the structure that is disclosed among the JP 09188625A BDerivative.

Other the open publications and the publication of open SGLT2 inhibitor comprise following:

K.Tsujihara etc., Chem.Pharm.Bull.44,1174-1180 (1996)

M.Hongu etc., Chem.Pharm.Bull.46,22-33 (1998)

M.Hongu etc., Chem.Pharm.Bull.46,1545-1555 (1998)

A.Oku etc., Diabetes.48,1794-1800 (1999)

JP 10245391 (Dainippon) discloses 500 structures as the hypoglycemic agents of treatment diabetes.These structures are the O-glucoside of hydroxylated tonka bean camphor.

WO 98/31697 discloses the compound of following structure

Wherein Ar comprises phenyl, xenyl, ditan, diphenylethane and diphenyl ether, and R ¹Be glucoside, R ²Be H, OH, amino, halogen, carboxyl, alkyl, cycloalkyl or formamido-, R ³For hydrogen, alkyl or acyl group and k, m and n independently are 1-4.A subgroup of WO 98/31697 disclosed compound comprises the compound of following structure

They are disclosed and are used for the treatment of or prevent inflammatory diseases, autoimmune disorder, infection, cancer and cancer metastasis, pour into disease, thrombosis, ulcer, wound, osteoporosis, diabetes and atherosclerosis and other diseases again.

Invention is described

According to the present invention, provide C-aryl glucoside compound and pharmacy acceptable salt, its all steric isomer and all prodrug esters thereof with following structure I:

Wherein

R ¹, R ²And R ^2aIndependent is hydrogen, OH, OR ⁵, alkyl, CF ₃, OCHF ₂, OCF ₃, SR ⁵ⁱOr halogen, or R ¹, R ²And R ^2aIn two can form 5,6 or 7 yuan of carbocyclic rings that increase ring with the carbon that they connected or can on ring, contain 1-4 and be N, O, S, SO and/or SO ₂Heteroatomic heterocycle;

R ³And R ⁴Independent is hydrogen, OH, OR ^5a, O aryl, OCH ₂Aryl, alkyl, cycloalkyl, CF ₃,-OCHF ₂,-OCF ₃, halogen ,-CN ,-CO ₂R ^5b,-CO ₂H ,-COR ^6b,-CH (OH) R ^6c,-CH (OR ^5h) R ^6d,-CONR ⁶R ^6a,-NHCOR ^5c,-NHSO ₂R ^5d,-NHSO ₂Aryl, aryl ,-SR ^5e,-SOR ^5f,-SO ₂R ^5g,-SO ₂Aryl, or can on ring, contain 1-4 and be N, O, S, SO and/or SO ₂Heteroatomic 5,6 or 7 yuan of heterocycles; Perhaps R ³And R ⁴Forming 5,6 or 7 yuan of carbocyclic rings that increase ring or can contain 1-4 on ring with the carbon that they connected is N, O, S, SO and/or SO ₂Heteroatomic heterocycle;

R ⁵, R ^5a, R ^5b, R ^5c, R ^5d, R ^5e, R ^5f, R ^5g, R ^5hAnd R ⁵ⁱIndependent is alkyl;

R ⁶, R ^6a, R ^6b, R ^6cAnd R ^6dIndependent is hydrogen, alkyl, aryl, alkaryl or cycloalkyl, or R ⁶And R ^6aForm with the nitrogen that they connected and on ring, to contain 1-4 and be N, O, S, SO and/or SO ₂Heteroatomic increase the ring 5,6 or 7 yuan of heterocycles;

A is O, S, NH or (CH ₂) _n, wherein n is 0-3.

Formula I compound of the present invention as defined above also comprises such precondition: when A is (CH ₂) _n, wherein n be 0,1,2 or 3 or A be O, and R ¹, R ²And R ^2aIn at least one be OH or OR ⁵The time, R then ¹, R ²And R ^2aIn at least one be CF ₃, OCF ₃Or OCHF ₂And/or R ³And R ⁴In at least one be CF ₃,-OCHF ₂,-OCF ₃, CH (OR ^5h) R ^6d, CH (OH) R ^6c, COR ^6b,-CN ,-CO ₂R ^5b,-NHCOR ^5c,-NHSO ₂R ^5d,-NHSO ₂Aryl, aryl ,-SR ^5e,-SOR ^5f,-SO ₂R ^5gOr-SO ₂Aryl.

Preferred as defined above formula I compound comprises such precondition: when A is (CH ₂) _n, wherein n be 0,1,2 or 3 or A be O, and R ¹, R ², R ^2a, R ³And R ⁴In at least one be OH or OR ⁵The time, R then ¹, R ²And R ^2aIn at least one be CF ₃, OCF ₃Or OCHF ₂And/or R ³And R ⁴In at least one be CF ₃,-OCHF ₂,-OCF ₃,-CN ,-CO ₂R ^5b, CH (OR ^5h) R ^6d,-NHCOR ^5c,-NHSO ₂R ^5d,-NHSO ₂Aryl, aryl ,-SR ^5e,-SOR ^5f,-SO ₂R ^5g,-SO ₂Aryl or halogen.

Formula I compound has as the activity that is found in the inhibitor of the sodium dependent glucose translocator in mammiferous enteron aisle and the kidney, thereby be used for the treatment of the capillary blood vessel and the great vessels complication of diabetes and diabetes, as retinopathy, neuropathy, ephrosis and wound healing.

The invention provides formula I compound, use the medicinal compositions of such compound and use the method for such compound.

In addition, according to the present invention, provide the method for the treatment of or delaying following advancing of disease or outbreak: diabetes, particularly I type and type ii diabetes, comprise that diabetic complication (comprises retinopathy, neuropathy, ephrosis and delay wound healing), and relative disease such as insulin resistance (glucose homeostasis is impaired), hyperglycemia, hyperinsulinemia, the blood level of the rising of lipid acid or glycerine, obesity, hyperlipidaemia (comprises hypertriglyceridemia, X syndrome, atherosclerosis and hypertension, and being used to increase the method for hdl level, the compound of wherein treating the structure I of significant quantity is given the patient who needs treatment.

In addition, according to the present invention, provide a kind of treatment as before this and the diabetes of definition after this and the method for relative disease, the composition of wherein treating the therapeutical agent of the antidiabetic medicine of compound and another type of structure I of significant quantity and/or another type such as hypolipidemic is given needs the patient that treat.

The illness, disease and the illness that are referred to as " X syndrome " (being also referred to as metabolism syndrome) are specified in Johannsson J.Clin.Endocrinol.Metab., 82, among the 727-34 (1997).

Term used herein " therapeutical agents of other types " refers to one or more antidiabetic medicine (the SGLT2 inhibitor of non-formula I), one or more anti-obesity medicine, antihypertensive drug, antiplatelet drug, Antiatherosclerosis medicine and/or one or more hypolipidemics (comprising Antiatherosclerosis medicine).

In above method of the present invention, the structure I compound of the present invention that uses with described a kind of, two or more antidiabetic medicine and/or a kind of weight ratio of therapeutical agent (depending on its binding mode) of, two or more other types at about 0.01: 1 to about 300: 1, preferably about 0.1: 1 to about 10: 1 scope

The compound of preferred formula IA

Wherein A is CH ₂Or O or S and be connected in glucoside between the position;

R ¹, R ²And R ^2aIndependently be selected from hydrogen, low alkyl group, halogen, OR ⁵Or OCHF ₂, perhaps R ¹, R ²And R ^2aIn two be H, and another is low alkyl group, halogen, OR ⁵Or OCHF ₂

R ³And R ⁴Independently be selected from low alkyl group, OR ^5a,-OCHF ₂,-SR ^5e, OH ,-CO ₂R ^5b,-3,4-(OCH ₂O)-,-COR ^6b,-CH (OH) R ^6c,-CH (OR ^5h) R ^6d, CF ₃,

,-SOR ^5f,-SO ₂R ^5g, aryl ,-NHSO ₂Aryl ,-NHSO ₂R ^5d, COOH, thiadiazoles, tetrazolium ,-OCH ₂Aryl ,-OCF ₃, O aryl or H.

More preferably such formula I compound, wherein A is CH ₂

R ¹Be hydrogen, halogen or low alkyl group;

R ²And R ^2aRespectively be H;

R ³Be H;

R ⁴For low alkyl group ,-COR ^6b,-CH (OH) R ^6c,-CH (OR ^5h) R ^6d, R ^5aO ,-OCHF ₂,-OCF ₃Or-SR ^5e

The formula I compound of most preferred configuration IB

R wherein ¹Be hydrogen, halogen or low alkyl group and R ⁴Be low alkyl group, R ^5aO ,-OCHF ₂Or-SR ^5ePreferred R ¹Be connected in the glucoside bond contraposition and R ⁴Substituting group is connected in the contraposition.

Detailed Description Of The Invention

Preparation shown in formula I compound of the present invention can and be described as following reaction process, wherein temperature is with a degree centigrade expression.

Shown in flow process 1, at catalyzer as 1) in the presence of the Pd/C, use solvent such as methyl alcohol or ethanol, perhaps 2) preferably in the presence of palladium hydroxide, use solvent such as ethyl acetate, by usefulness hydrogen treat formula II compound,

(wherein Bn=benzyl) can preparation I compound.Perhaps, at-78 ℃, by sour as boron tribromide, boron trichloride or BCl with Lewis ₃Me ₂S handles formula II compound in solvent such as methylene dichloride, can preparation I compound.In 20 ℃, by at solvent as containing BF ₃Et ₂Handle formula II compound among the EtSH of O, also can preparation I compound.

In-30 ℃, by using silane such as Et ₃SiH or preferred (iPr) ₃SiH is at solvent such as MeCN or contain Lewis acid as BF ₃Et ₂Handle the formula III compound in the mixture of the MeCN/ methylene dichloride of O, can preparation formula II compound (it is new intermediate).

Formula III compound (it is new intermediate) can through type IV compound

Coupling preparation with formula V compound.

Before adding lactone V, in-78 ℃, by in solvent such as THF, handle, can activate the formula IV compound that is used for coupling with n-Butyl Lithium or tert-butyl lithium.The preparation of lactone V is described in R.Benhaddou, S Czernecki etc., and Carbohydr.Res., 260 (1994), among the 243-250.

Flow process 1

Shown in flow process 2,, sour as containing Lewis as BF at solvent in-30 ℃ to+60 ℃ ₃Et ₂Among the MeCN or methylene dichloride of O or TFA, by using silane such as Et ₃SiH handles formula VI compound

Can preparation formula IV compound, wherein A is (CH ₂) _n, n=1-3 wherein.

The condition that adopts those skilled in the art to be familiar with is in the solvent such as ether or THF, by making the bromobenzene formaldehyde of the formula VII that is commercially available

With the Organometallic derivatives coupling of the lithium or the magnesium of formula VIII compound,

Can preparation formula VI compound.

Formula VIII compound or for being commercially available perhaps can easily prepare by standard method well known by persons skilled in the art.

Flow process 2

By the order with 1) acetylizing agent such as Ac ₂O is at solvent such as simple pyridine or contain in the methylene dichloride of 1.5 normal alkali such as triethylamine 2) reductive agent such as sodium borohydride in solvent such as ethanol, 3) alkylating agent such as R ^5hBr or R ^5hI in the presence of alkali such as NaH, in solvent such as DMF and 4) ester alkaline hydrolysis condition such as lithium hydroxide in 2: 3: 1 mixture of THF/ methanol, handle wherein R ⁴Be COR ^6bFormula I compound, can prepare wherein R ⁴Be CH (OR ^5h) R ^6dFormula I compound.

By using reductive agent such as sodium borohydride in solvent such as ethanol, handle wherein R ⁴Be COR ^6bFormula I compound, can prepare wherein R ⁴Be CH (OH) R ^6cFormula I compound.

At-78 ℃, by in solvent such as methylene dichloride, handling wherein R as boron trichloride or boron tribromide with Lewis acid ⁴Be COR ^6bFormula II compound, can prepare wherein R ⁴Be COR ^6bFormula I compound.

Shown in flow process 3, catalyzer close as four (triphenyl phosphines) palladium in the presence of, by making formula IX compound can be commercially available that buy or that obtain easily

Wherein Z is bromine or chlorine, with formula X compound

Makes this two kinds of composition couplings through heating in solvent such as PhMe, can preparation formula II compound, wherein A is CH ₂And R ⁴For-COR ^6b

By using (Bu ₃Sn) ₂Close palladium with catalyzer as four (triphenyl phosphines) and in solvent such as toluene, handle, can be by formula XI compound

Preparation formula X compound (it is new intermediate).

In-30 ℃, by using silane such as iPr ₃SiH or Et ₃SiH is sour as BF as containing Lewis at solvent ₃Et ₂Handle among the MeCN of O, can be by formula XII compound

Preparation formula XI compound (it is new intermediate).

Formula XH compound (it is new intermediate) can prepare by making formula V compound and organolithium coupling, and organolithium can be by in-78 ℃, handles formula XIII compound and obtain in THF with n-Butyl Lithium or tert-butyl lithium

Flow process 3

Wherein A is CH ₂The another kind of synthetic method (flow process 4) of formula IV compound be with reductive agent such as Et ₃SiH at solvent as containing catalyst B F ₃Et ₂Reduction-type XIV compound carries out in the MeCN of O or methylene dichloride or its mixture.

By such as containing in the dithiocarbonic anhydride solvent of 2 normal Lewis acid as aluminum chloride or alchlor, use the acyl chlorides of the formula XVI that obtains easily

With the formula XV hydrocarbon Friedel-Craft acidylate that is commercially available,

Preparation formula XIV compound easily.

Flow process 4

Shown in flow process 5, by making formula XI compound and formula XVII compound

Or corresponding boric acid XVIII coupling, can preparing wherein, A is the formula II compound of key.

3: 1 solvents of PhMe/ alcoholic acid of yellow soda ash are used as contain in described coupling, catalyzer close as four (triphenyl phosphines) palladium in the presence of heat and carry out.Formula XVIII compound or be commercially available, perhaps available boron trichloride handles formula XVII compound in solvent such as methylene dichloride.Formula XVII compound can by at solvent as containing catalyzer such as PdCl ₂Heating-type XIX compound among the DMSO of dppf and alkali such as KOAc

X prepares with compounds X.

Flow process 5

Shown in flow process 6, handle formula XXI compound with alkali such as sodium hydride earlier

Then in solvent such as PhMe, heat with formula IX compound, can preparation formula II compound, wherein A=CH ₂And R ²=OH.

In-30 ℃, by using silane such as Et ₃SiH or iPr ₃SiH is sour as BF as containing Lewis at solvent ₃Et ₂Handle among the MeCN of O, can be by formula XXII compound

Preparation formula XXI compound.

Formula XXII compound can prepare by the metal derivative coupling that makes formula V compound and activatory formula XXIII compound, the latter can be by handling with alkali such as sodium hydride, potassium hydride KH or potassium tert.-butoxide earlier, then handles in solvent such as anhydrous THF with lithium alkylide such as n-Butyl Lithium or tert-butyl lithium and prepare.

Flow process 6

Shown in flow process 7, by at solvent as containing alkali such as triethylamine, catalyzer such as Cu (OAc) ₂With heat in the pyridine of molecular sieve, make formula XXIV compound

With the formula XXV compound coupling that is commercially available,

Wherein X=O or NH can preparation I compound, wherein A=O or NH.

In-78 ℃, in solvent such as methylene dichloride, handle the compound of formula XXVI with boron trichloride

Can preparation formula XXIV compound (it is new intermediate).

Formula XXVI compound (it is new intermediate) can by at solvent as containing catalyzer such as PdCl ₂Heating-type XI compound and formula XX compound prepare among the DMSO of dppf and alkali such as KOAc.

Flow process 7

Shown in flow process 8, by at solvent as containing alkali such as triethylamine, catalyzer such as Cu (OAc) ₂With heat in the pyridine of molecular sieve, make formula XVIII compound

With the coupling of formula XXVII compound,

Wherein X=O or NH can preparation formula IV compound, wherein A=O or NH.

Flow process 8

Shown in flow process 9, by making the aryl bisulphide of formula XXVIII

With organolithium (, in THF, making the acquisition of formula XIII compound metal) coupling with n-Butyl Lithium or tert-butyl lithium in-78 ℃, can preparation formula IV compound, wherein A is S.

Flow process 9

Various terms used in the specification sheets of the present invention are defined as follows.No matter these definition are independent uses when being used for specification sheets full text, or as the part than macoradical, all are applicable to described term (unless they are limited in addition) in concrete example.

This paper uses following shortenings:

The Ph=phenyl

The Bn=benzyl

The t-Bu=tertiary butyl

The Me=methyl

The Et=ethyl

The TMS=trimethyl silyl

TMSN ₃=trimethyl silyl trinitride

The TBS=t-butyldimethylsilyl

The THF=tetrahydrofuran (THF)

Et ₂The O=ether

The EtOAc=ethyl acetate

The DMF=dimethyl formamide

MeOH=methyl alcohol

EtOH=ethanol

The i-PrOH=Virahol

HOAc or AcOH=acetate

The TFA=trifluoroacetic acid

I-Pr ₂The NEt=diisopropylethylamine

Et ₃The N=triethylamine

The DMAP=4-dimethyl aminopyridine

NaBH ₄=sodium borohydride

LiAlH ₄=lithium aluminum hydride

The n-Buli=n-Butyl Lithium

The Pd/C=palladium on carbon

KOH=potassium hydroxide

NaOH=sodium hydroxide

The LiOH=lithium hydroxide

K ₂CO ₃=salt of wormwood

NaHCO ₃=sodium bicarbonate

EDC (or EDCHCl) or EDCI (or EDCIHCl) or EDAC=3-ethyl-3 '-(dimethylamino) propyl group-carbodiimide hydrochloride (or 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride)

HOBT or HOBTH ₂The O=1-hydroxy benzotriazole hydrate

HOAT=1-hydroxyl-7-azepine benzotriazole

Ph ₃The P=triphenyl phosphine

Pd (OAc) ₂=acid chloride

(Ph ₃P ₎4Pd °=four (triphenyl phosphines) close palladium

The Ar=argon gas

N ₂=nitrogen

Min=minute

H or hr=hour

The L=liter

The mL=milliliter

μ l=microlitre

The g=gram

The mg=milligram

The mol=mole

The mmol=mmole

The meq=milliequivalent

The RT=room temperature

Sat or sat ' d=are saturated

Aq.=is aqueous

The TLC=thin-layer chromatography

The HPLC=high performance liquid chromatography

LC/MS=high performance liquid chromatography/mass spectrum

MS or Mass Spec=mass spectrum

The NMR=nucleus magnetic resonance

The mp=fusing point

Dppf=diphenylphosphine acyl Ferrocene (ferrocene)

Except as otherwise noted; term " low alkyl group " is when this uses separately or as the part of another group; comprise the straight chain and the branched-chain hydrocarbon that contain 1-8 carbon atom; term " alkyl " and " alk " are when this uses separately or as the part of another group; comprise and contain 1-20 carbon atom; preferred 1-10 carbon atom; in straight chain; the more preferably straight chain of 1-8 carbon atom and branched-chain hydrocarbon; methyl for example; ethyl; propyl group; sec.-propyl; butyl; the tertiary butyl; isobutyl-; amyl group; hexyl; isohexyl; heptyl; 4; 4-dimethyl amyl group; octyl group; 2; 2; the 4-tri-methyl-amyl; nonyl; decyl; undecyl; dodecyl; its various branched chain isomers etc., and comprise following substituent this type of group of 1-4: for example halogeno-group such as fluorine; bromine; chlorine or iodine or trifluoromethyl; alkyl; alkoxyl group; aryl; aryloxy; aryl (aryl) or diaryl; aralkyl; alkoxy aryl; alkenyl; alkynyl group; cycloalkyl; cycloalkenyl group; cycloalkylalkyl; cycloalkyl alkoxy; the optional amino that replaces; hydroxyl; hydroxyalkyl; acyl group; alkanoyl; heteroaryl; heteroaryloxy; Heterocyclylalkyl; the aryl heteroaryl; aromatic alkoxy carbonyl; heteroaralkyl; assorted aralkoxy; aryloxy alkyl; the aryloxy aryl; alkylamino; alkanoyl amino; aryl-amino-carbonyl; nitro; cyano group; thiol; haloalkyl; tri haloalkyl and/or alkylthio.

Except as otherwise noted, term " cycloalkyl " is when this uses separately or as the part of another gene, comprise and contain (containing 1 or 2 two key) 1-3 ring filling or fractional saturation cyclic hydrocarbon radical, comprise monocycle alkyl, bicyclic alkyl and tricyclic alkyl, contain the carbon atom of 3-20 altogether that forms ring, be preferably formed 3-10 carbon atom of ring, described ring can condense in 1 or 2 as to aryl on the described aromatic ring, it comprise cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, suberyl, ring octyl group, ring decyl and cyclo-dodecyl, cyclohexenyl,

In these groups any one can be by the following substituting group of 1-4 optional replacement: for example halogen, alkyl, alkoxyl group, hydroxyl, aryl, aryloxy, aralkyl, cycloalkyl, alkylamino, alkanoyl amino, oxo base, acyl group, aryl-amino-carbonyl, amino, nitro, cyano group, thiol and/or alkylthio and/or any alkyl substituent.

Term " cycloalkenyl group " refers to contain 3-12 carbon atom, the cyclic hydrocarbon of preferred 5-10 carbon atom and 1 or 2 pair of keys when this uses separately or as the part of another group.The example of cycloalkenyl group comprises cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctene base, cyclohexadienyl and cycloheptadiene base, and it can be as the definition to cycloalkyl, optional being substituted.

Term " alkanoyl " refers to the alkyl that is connected with carbonyl when this uses separately or as the part of another group.

Except as otherwise noted; term " low-grade alkenyl " is when this uses with itself or as the part of another group; the straight or branched group that refers to 2-8 carbon atom; and term " alkenyl " is when this uses with itself or as the part of another group; refer to 2-20 carbon atom; preferred 2-12 carbon atom; the straight or branched group that 2-8 carbon atom more preferably arranged on straight chain; it is included in 1-6 two key on the straight chain; as vinyl; the 2-propenyl; the 3-butenyl; crotyl; the 4-pentenyl; the 3-pentenyl; the 2-hexenyl; the 3-hexenyl; the 2-heptenyl; the 3-heptenyl; the 4-heptenyl; the 3-octenyl; 3-nonene base; 4-decene base; 3-hendecene base; 4-laurylene base; 4; 8; 12-14 carbon trialkenyl etc., and it can replace by a following 1-4 substituting group is optional: i.e. halogen; haloalkyl; alkyl; alkoxyl group; alkenyl; alkynyl group; aryl; aralkyl; cycloalkyl; amino; hydroxyl; heteroaryl; Heterocyclylalkyl; alkanoyl amino; alkyl amido; aryl-amino-carbonyl; nitro; cyano group; thiol; any alkyl substituent that alkylthio and/or this paper propose.

Except as otherwise noted; term " alkynyl of low-grade chain " is when this uses with itself or as the part of another group; the straight or branched group that refers to 2-8 carbon atom; and term " alkynyl group " is when this uses with itself or as the part of another group; refer to 2-20 carbon atom; preferred 2-12 carbon atom; the straight or branched group that 2-8 carbon atom more preferably arranged on straight chain; it is included in 1 triple bond on the straight chain; as 2-propynyl; the 3-butynyl; the 2-butyne base; the 4-pentynyl; the 3-pentynyl; 2-hexin base; 3-hexin base; 2-heptyne base; 3-heptyne base; 4-heptyne base; 3-octyne base; 3-n-heptylacetylene base; the 4-decynyl; 3-undecyne base; 4-dodecyne base etc.; and it can replace by a following 1-4 substituting group is optional: i.e. halogen; haloalkyl; alkyl; alkoxyl group; alkenyl; alkynyl group; aryl; aralkyl; cycloalkyl; amino; heteroaryl; Heterocyclylalkyl; hydroxyl; alkanoyl amino; alkyl amido; aryl-amino-carbonyl; nitro; cyano group; thiol and/or alkylthio, and/or any alkyl substituent of this paper proposition.

When term " aralkyl ", " aralkenyl " and " aralkynyl " use separately or as the part of another group, refer to have aforesaid alkyl, alkenyl and the alkynyl group of aryl substituent.

When alkyl group as defined above had the singly-bound that connects other groups on two different carbon atoms, they were known as " alkylidene group " and can be as above the definition of " alkyl " be optionally substituted.

When alkenyl as defined above and alkynyl group as defined above have respectively when being connected two singly-bounds on the different carbon atoms, they are respectively referred to as " alkylene group " and " inferior alkynyl group ", and can be as above the definition of " alkenyl " and " alkynyl group " be optionally substituted.

Suitable as defined herein alkylidene group, alkylene group or inferior alkynyl group (CH ₂) _mOr (CH ₂) _p(wherein p is 1-8, preferred 1-5 and m are 1-5, preferred 1-3, it comprises alkylidene group, alkylene group or inferior alkynyl group) can choose wantonly and comprise 1,2 or 3 substituting group, described substituting group comprises alkyl, alkenyl, halogen, cyano group, hydroxyl, alkoxyl group, amino, alkylthio, ketone group, C ₃-C ₆Cycloalkyl, alkyl-carbonyl-amino or alkyl-carbonyl oxygen base.

(CH ₂) _mOr (CH ₂) _p, the example of alkylidene group, alkylene group and inferior alkynyl group comprises-CH ₂-,-CH ₂CH ₂-,

Term " halogen " or " halogeno-group " refer to chlorine, bromine, fluorine and iodine, and chlorine or fluorine are preferred when this uses separately or as the part of another group.

Term " metal ion " refers to alkalimetal ion such as sodium, potassium or lithium and alkaline-earth metal ions such as magnesium and calcium and zinc and aluminium.

Except as otherwise noted, term " aryl " is when this uses separately or as the part of another group, finger contains the monocycle and the bicyclic aromatic group (comprising 1-naphthyl and 2-naphthyl as phenyl or naphthyl) of 6-10 carbon at loop section, and can choose wantonly and comprise and condensing in carbocyclic ring or heterocyclic 1-3 other ring (as aryl, cycloalkyl, heteroaryl or heterocycloalkyl ring, for example

And can be by available carbon atom by being selected from following 1; 2 or 3 optional replacements of group: hydrogen; halogeno-group; haloalkyl; alkyl; haloalkyl; alkoxyl group; halogenated alkoxy; alkenyl; trifluoromethyl; trifluoromethoxy; alkynyl group; cycloalkyl-alkyl; Heterocyclylalkyl; the Heterocyclylalkyl alkyl; aryl; heteroaryl; aralkyl; aryloxy; aryloxy alkyl; aralkoxy; alkoxy carbonyl; aryl carbonyl; aromatic yl alkenyl; the aminocarboxyl aryl; arylthio; the aryl sulfinyl; the arylazo base; heteroarylalkyl; the heteroaryl alkenyl; the heteroaryl heteroaryl; heteroaryloxy; hydroxyl; nitro; cyano group; amino; the amino that replaces, wherein amino comprises that (it is alkyl to 1 or 2 substituting group; any other aryl compound of mentioning in aryl or the definition); thiol; alkylthio; arylthio; heteroarylthio; arylthio alkyl; the alkoxy aromatic sulfenyl; alkyl-carbonyl; aryl carbonyl; alkyl amino-carbonyl; aromatic yl aminocarbonyl; alkoxy carbonyl; aminocarboxyl; the alkyl-carbonyl oxygen base; aryl carbonyl oxygen base; alkyl-carbonyl-amino; aryl-amino-carbonyl; the aryl sulfinyl; aryl sulfinyl alkyl; arlysulfonylamino and Arenesulfonyl amino (sulfonamino) carbonyl and/or at any alkyl substituent of this proposition.

Except as otherwise noted, term " lower alkoxy ", " alkoxyl group ", " aryloxy " or " aralkoxy " comprise any abovementioned alkyl, aralkyl or the aryl that are connected in Sauerstoffatom when this uses separately or as the part of another group.

Except as otherwise noted, term " amino of replacement " is when this uses separately or as the part of another group, the amino that finger is replaced by one or two substituting group, these substituting groups can be identical or different, for example are alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, Heterocyclylalkyl, Heterocyclylalkyl alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl and alkylthio.These substituting groups can further be replaced by carboxylic acid and/or any alkyl substituent of listing above.In addition; described amino substituting group can form 1-pyrrolidyl, piperidino, 1-azepine  base, 4-morpholinyl, 4-thio-morpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-aralkyl-1-piperazinyl, 4-alkyl diaryl-1-piperazinyl, 1-pyrrolidyl, piperidino or 1-azepine  base with the nitrogen-atoms that they connect, and is optional by alkyl, alkoxyl group, alkylthio, halogeno-group, trifluoromethyl or hydroxyl replacement.

Except as otherwise noted, term " lower alkylthio ", " alkylthio " " arylthio " or " alkylthio-aryl " comprise any abovementioned alkyl, aralkyl or the aryl that are connected in sulphur atom when this uses separately or as the part of another group.

Except as otherwise noted, term " low-grade alkyl amino ", " alkylamino " " arylamino " or " aryl-alkyl amino " comprise any abovementioned alkyl, the aryl or aralkyl that are connected in nitrogen-atoms when this uses separately or as the part of another group.

Except as otherwise noted, term " acyl group " with itself or as when the part of another group of this definition is used, refers to be connected in carbonyl at this

Organic group; The example of acyl group comprises any alkyl substituent that is connected in carbonyl, as alkanoyl, alkenoyl, aroyl, Arylalkanoyl, 4-hetaroylpyrazol, cycloalkanes acyl group, heterocycle alkyloyl etc.

Except as otherwise noted, term " Heterocyclylalkyl " is when this uses separately or as the part of another group, refer to comprise the saturated or undersaturated ring of part of 5-, 6-or 7-unit of 1-2 heteroatoms (as nitrogen, oxygen and/or sulphur), described heteroatoms may be crossed linking group (CH by former gating by carbon atom or heteroatoms ₂) _p(wherein p is 1,2 or 3) connects, for example

Deng.Above group can comprise 1-4 substituting group, as alkyl, halogeno-group, oxo base and/or at this any alkyl substituent of listing.In addition, any heterocycloalkyl ring can condense on cycloalkyl, aryl, heteroaryl or heterocycloalkyl ring.

Except as otherwise noted, term " heteroaryl " is when this uses separately or as the part of another group, refer to comprise the 5-or the 6-unit aromatic ring of 1,2,3 or 4 heteroatoms (as nitrogen, oxygen or sulphur), and such ring condenses on aryl, cycloalkyl, heteroaryl or heterocycloalkyl ring (as benzothienyl or indyl), and may comprise the N-oxide compound.Described heteroaryl can be chosen wantonly and comprise 1-4 substituting group, as above-mentioned any alkyl substituent.The example of heteroaryl comprises following group:

Deng.

Term " Heterocyclylalkyl alkyl " refers to be connected in (CH by carbon atom or heteroatoms when this uses separately or as the part of another group ₂) _pHeterocyclylalkyl as defined above on the chain.

Term " heteroaralkyl " or " heteroaryl alkenyl " refer to be connected in as defined above-(CH by carbon atom or heteroatoms when this uses separately or as the part of another group ₂) _pHeteroaryl as defined above on-chain, alkylidene group or the alkylene group.

Term " 5,6 or 7 yuan carbocyclic ring or heterocycle " refers to as defined above cycloalkyl or cycloalkenyl group or heteroaryl or heterocyclic aryl as defined above, as thiadiazoles, tetrazolium, imidazoles or  azoles when this uses.

Term " multi-haloalkyl " refers to comprise 2-9 when this uses, preferred 2-5 halo substituting group, and as fluorine or chlorine, " alkyl " as defined above of preferred fluorine is as CF ₃CH ₂, CF ₃Or CF ₃CF ₂CH ₂

Term " many halogenated alkoxies " refers to comprise 2-9 when this uses, preferred 2-5 halo substituting group, and as fluorine or chlorine, " alkoxyl group " as defined above or " alkyl oxy " of preferred fluorine are as CF ₃CH ₂O, CF ₃O or CF ₃CF ₂CH ₂O.

Term " prodrug ester " is when this uses; comprise the method that adopts generation acetic ester well known by persons skilled in the art, pivalate, methyl carbonic, benzoic ether etc.; one or more hydroxyl by making formula I compound and alkyl, alkoxyl group, or the aryl formed ester of acylation reaction and the carbonic ether that replace.In addition, prodrug ester known in the art has carboxylicesters and phosphoric acid ester such as their methyl esters, ethyl ester, benzyl ester etc.

The example of this type of prodrug ester comprises

When the compound of structure I is the form of acid, they can form pharmacy acceptable salt such as an alkali metal salt such as lithium, sodium or sylvite, the salt of alkaline earth salt such as calcium or magnesium salts and zinc or aluminium salt and other positively charged ion such as ammonium, choline, diethanolamine, Methionin (D or L), quadrol, TERTIARY BUTYL AMINE, uncle-octyl amine, three-(methylol) aminomethane (TRIS), N-methylglucosamine (NMG), trolamine and dihydro abietyl amine.

Plan comprises all steric isomers of The compounds of this invention, no matter is form of mixtures, or pure form or pure substantially form.The compounds of this invention can have asymmetric center on any carbon atom (comprising any one in the R substituting group).Like this, formula I compound can exist with the form of enantiomorph or diastereomer form or its mixture.The preparation method can use racemic modification, enantiomorph or diastereomer as raw material.When preparation diastereomer or enantiomorph product, they can pass through ordinary method, and for example, chromatography or fractional crystallization separate.

When needing, the compound of structure I can be used for and the antidiabetic medicine of one or more other types and/or the therapeutical agent Combined Preparation of one or more other type, and they can be with same formulation, give with the oral dosage form orally give that separates or through injection.

Can choose the antidiabetic medicine that is used for uniting with the SGLT2 inhibitor of formula I other type that gives wantonly can be 1,2,3 or more kinds of antidiabetic medicine or hyperglycemia medicine, comprise Regular Insulin, secretogogue or euglycemic agent, or other antidiabetic medicine, the antidiabetic medicine that preferably has the mechanism of action different with the SGLT2 inhibition, and can comprise the biguanide class, sulfonylurea, alpha-glucosidase inhibitors, PPAR gamma agonist such as thiazolidinedione, the aP2 inhibitor, PPAR α/γ dual agonists, DPP IV (DP4) inhibitor and/or meglitinide, and Regular Insulin, hyperglycemic-glycogenolytic factor-sample peptide-1 (GLP-1), the PTPlB inhibitor, glycogen phosphorylase inhibitors and/or Robison ester enzyme inhibitors.

The therapeutical agent that is used for uniting other type that gives be can choose wantonly and anti-obesity medicine, antihypertensive drug, antiplatelet drug, Antiatherosclerosis medicine and/or hypolipidemic comprised with the SGLT2 inhibitor of formula I.

The SGLT2 inhibitor of formula I also can be chosen wantonly and be used for giving with treatment the medication combined of diabetic complication.These medicines comprise pkc inhibitor and/or AGE inhibitor.

Believe structure I compound and 1,2,3 or more kinds of other antidiabetic medicine unite the hyperglycemia effect that use to produce greater than using each of these medicines can obtainable effect separately, and the adding and the hyperglycemia effect of the associating that produces greater than these medicines.

Other antidiabetic medicine can be oral hyperglycemia medicine, preferred biguanide class such as N1,N1-Dimethylbiguanide or phenformin or its salt, preferred Metformin.

When other antidiabetic medicine is the biguanide time-like, the weight ratio of the compound of used structure I and biguanide class will be at about 0.01: 1 to about 100: 1, preferably in about 0.1: 1 to about 5: 1 scope.

Other antidiabetic medicine also can be preferably sulfonylurea such as Glyburide (being also referred to as glyburide), glimepiride No. 4379785, United States Patent (USP) (be disclosed in), Glipizide, gliclazide or P-607, other known sulfonylureas or other act on the hyperglycemia medicine of the ATP-dependency passage of beta cell, be preferably Glyburide and Glipizide, it can be with oral dosage form administration same or that separate.

The compound of structure I can with the weight ratio of sulfonylurea at about 0.01: 1 to about 100: 1, preferably to about 10: 1 scope, used at about 0.2: 1.

The oral antidiabetic thing also can be an alpha-glucosidase inhibitors, and as acarbose No. 4904769, United States Patent (USP) (be disclosed in) or miglitol No. 4639436, United States Patent (USP) (be disclosed in), it can be with oral dosage form administration same or that separate.

The compound of structure I can with the weight ratio of alpha-glucosidase inhibitors at about 0.01: 1 to about 100: 1, preferably to about 50: 1 scope, used at about 0.5: 1.

The compound of structure I can with PPAR gamma agonist such as thiazolidinedione oral antidiabetic thing or other euglycemic agent (it has the effect that strengthens insulin sensitivity in NIDDM patient) as the troglitazone (Rezulin of Warner-Lambert ^Be disclosed in the United States Patent (USP) 4572912), GL-262570, the englitazone (CP-68722 of the MCC-555 of rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi No. 5594016, United States Patent (USP) (be disclosed in), Glaxo-Welcome, Pfizer) or darglitazone (CP-86325, Pfizer), isaglitazone (MIT/J﹠amp; J), JTT-501 (JPNT/P﹠amp; U), L-895645 (Merck), R-119702 (Sankyo/WL), NN-2344 (Dr.Reddy/NN), or YM-440 (Yamanouchi), preferred rosiglitazone and pioglitazone be Combined Preparation together.

The compound of structure I can with the weight ratio of thiazolidinedione at about 0.01: 1 to about 100: 1, preferably the amount in about 0.2: 1 to about 10: 1 scope is used.

Sulfonylurea and thiazolidinedione can be blended in the tablet with the amount that the is lower than about 150mg oral antidiabetic thing compound with structure I.

The compound of structure I also can with hyperglycemia medicine such as Regular Insulin or with hyperglycemic-glycogenolytic factor-sample peptide-1 (GLP-1) as GTP-1 (1-36) acid amides, GLP-1 (7-36) acid amides, GLP-1 (7-37) (as disclosed in the United States Patent (USP) 5614492 of Habener, these disclosed contents are attached to herein by reference), and AC2993 (Amylen) and LY-315902 (Lilly) unite use, it can pass through in injection, the nose, or gives through skin or oral-cavity device.

When having N1,N1-Dimethylbiguanide, sulfonylurea such as Glyburide, glimepiride, glipyride, Glipizide, P-607 and gliclazide and alpha-glucosidase inhibitors acarbose, miglitol or Regular Insulin (injection, lung, cheek or oral) can be with aforesaid preparation medications, described in its amount and dosage such as Physician ' the s Desk Reference (PDR).

When existing, N1,N1-Dimethylbiguanide or its salt can be with the amount medications in the about 2000mg scope of about 500-every day, its can single dose or every day 1-4 divided dose give.

When existing, the thiazolidinedione antidiabetic medicine can be with the amount medication in the about 2000mg/ daily range of about 0.01-, its can single dose or every day 1-4 divided dose give.

When existing, Regular Insulin can use with preparation, described in its amount and dosage such as Physician ' the s DeskReference.

When existing, the GLP-1 peptide can be with oral cavity cheek preparation, give or parenteral gives by nasal cavity, and as described in the United States Patent (USP) No. 5346701 (TheraTech), 5614492 and 5631224, it is attached to herein by reference.

Other antidiabetic medicine also can be PPAR α/γ dual agonists such as AR-HO39242 (Astra/Zeneca), GW-409544 (Glaxo-Wellcome), KRP297 (Kyorin Merck) and exist " the new euglycemic agent that serves as the common part (coligand) of peroxisome proliferation-activated α acceptor (PPAR α) and PPAR γ by Murakami etc.PPAR α is activated the metabolic effect of abnormal lipids in the liver of Zucker obese rat "; Diabetes47; 1841-1847 (1998); reach disclosed those antidiabetic medicines in U.S. Provisional Application number 60/155400 (the attorney docket LA29) that submitted on September 22nd, 1999; its disclosure is attached to herein by reference; these medicines can adopt the formulation in this proposition, wherein is appointed as preferred compound and preferably uses at this.

Other antidiabetic medicine can be for example to be disclosed in U. S. application series number 09/391053 (submission on September 7th, 1999) and U.S. Provisional Application number 60/127745 (submission on April 5th, 1999) (attorney docket LA27 ^*) in the ap2 inhibitor, adopt as in the formulation of this proposition.Preferably in above application, be appointed as preferred compound.

Other antidiabetic medicine can be the DP4 inhibitor, for example be disclosed in WO99/38501, WO99/46272, WO99/67279 (PROBIODRUG), WO99/67278 (PROBIODRUG), WO99/61431 (PROBIODRUG), as by Hughes etc., Biochemistry, 38 (36), 11597-11603,1999 disclosed NVP-DPP728A (1-[[[2-[(5-cyanopyridine-2-yl) amino] ethyl] amino] ethanoyl]-2-cyano group-(S)-tetramethyleneimine) (Novartis) (preferably), as by Yamada etc., Bioorg.﹠amp; The disclosed TSL-225 of Med.Chem.Lett.8 (1998) 1537-1540 (tryptophyl-1,2,3,4-tetrahydroisoquinoline-3-formic acid), as by Ashworth etc., Bioorg.﹠amp; Med.Chem.Lett., the 6th volume, 22 phases, 1163-1166 page or leaf and 2745-2748 page or leaf (1996) disclosed 2-cyano group pyrrolidides and 4-cyano group pyrrolidides adopt the formulation of narrating in the above reference.

Can choose the meglitinide of uniting use with formula I compound of the present invention wantonly can be repaglinide, nateglinide (Novartis) or KAD 1229 (PF/Kissei), is preferred with the repaglinide.

The SGLT2 inhibitor of formula I can with the weight ratio of meglitinide, PPAR gamma agonist, PPAR α/γ dual agonists, ap2 inhibitor or DP4 inhibitor at about 0.01: 1 to about 100: 1, preferably to about 10: 1 scope, used at about 0.2: 1.

Can choose wantonly and unite the hypolipidemic of use or lipid lowering agent with formula I compound of the present invention and comprise 1,2,3 or more kinds of MTP inhibitor, HMG CoA reductase inhibitor, inhibitor for squalene synthetic enzyme, fibric acid derivative, ACAT inhibitor, lipoxygenase inhibitor, cholesterol absorption inhibitor, ileum Na ⁺/ cholic acid cotransporter inhibitor, the active rise thing of ldl receptor, cholic acid chelating agent and/or nicotinic acid and derivative thereof.

Comprise the MTP inhibitor that is disclosed in the following patent at this used MTP inhibitor: No. 5595872, United States Patent (USP), No. 5739135, United States Patent (USP), No. 5712279, United States Patent (USP), No. 5760246, United States Patent (USP), No. 5827875, United States Patent (USP), No. 5885983, United States Patent (USP) and U. S. application series number 09/175180 (submission on October 20th, 1998), No. 5962440, present United States Patent (USP).Each the preferred L TP inhibitor that is disclosed in above each part patent and the application all is preferred.More than all United States Patent (USP) and application be attached to herein by reference.

Hypolipidemic can be a HMG CoA reductase inhibitor, it comprises, but be not limited to, as be disclosed in mevastatin in No. 3983140, the United States Patent (USP) and related compound, as be disclosed in lovastatin (mevinolin) in No. 4231938, the United States Patent (USP) and related compound, as be disclosed in Pravastatin in No. 4346227, the United States Patent (USP) and related compound, as being disclosed in Simvastatin and the related compound in United States Patent (USP) 4448784 and No. 4450171.Hypolipidemic also can be the compound that is disclosed in the U.S. Provisional Application number 60/211594 and 60/211595.Comprise at this operable other HMG CoA reductase inhibitor, but be not limited to, as be disclosed in fluvastatin in No. 5354772, the United States Patent (USP), as be disclosed in cerivastatin in United States Patent (USP) 5006530 and No. 5177080, as be disclosed in United States Patent (USP) 4681893,5273995, atorvastatin in 5385929 and No. 5686104, as be disclosed in atavastatin (nisvastatin of Nissan/Sankyo (NK-104)) in No. 5011930, the United States Patent (USP), be disclosed in the Shionogi-Astra/Zeneca visastatin (XD-4522) in No. 5260440, the United States Patent (USP) and be disclosed in relevant his spit of fland (statin) compound in the United States Patent (USP) 5753675, as be disclosed in the pyrazole analogs of mevalonolactone (mevaloholactone) derivative in No. 4613610, the United States Patent (USP), as be disclosed in the indenes analogue of the mevalonolactone derivative among the PCT application WO 86/03488, as be disclosed in 6-[2-in No. 4647576, the United States Patent (USP) (replacement-pyrroles-1-yl)-alkyl] pyran-2-one and derivative thereof, the SC-45355 of Searle (glutaric acid derivatives that a kind of 3-replaces) dichloro-acetate, as be disclosed in the imidazoles analogue of the mevalonolactone among the PCT application WO 86/07054, as be disclosed in 3-carboxyl-2-hydroxyl-propane-phosphonate derivative in No. 2596393, the French Patent, as be disclosed in 2 in the European Patent Application No. 0221025,3-disubstituted pyrroles, furans and thiophene derivant, as be disclosed in the naphthyl analogue of the mevalonolactone in No. 4686237, the United States Patent (USP), as disclosed octahydro naphthalene in No. 4499289, the United States Patent (USP), as be disclosed in the ketone group analogue of the mevinolin (lovastatin) among the European Patent Application No. 0142146A2 and be disclosed in quinoline and pyridine derivate in United States Patent (USP) 5506219 and No. 5691322.

In addition, the phosphinic compounds that is suitable for being used for as used herein suppressing HMG CoA reductase enzyme is disclosed in GB 2205837.

Being suitable for as used herein, inhibitor for squalene synthetic enzyme comprises; but be not limited to, be disclosed in the α-phosphono-sulphonate of United States Patent (USP) 5712396 Shens; by Biller etc., J.Med.Chem.; 1988; the 31st volume, 10 phases, 1869-1871 page or leaf those disclosed compound; comprise isoprenoid (phosphinyl-methyl) phosphonic acid ester and other known inhibitor for squalene synthetic enzyme; for example, as United States Patent (USP) 4871721 and No. 4924024 and at Biller, S.A.; Neuenschwander; k., Ponpipom, M.M. and Poulter; C.D.; CurrentPharmaceutical Design, 2, disclosed among the 1-40 (1996).

In addition, be suitable for as used herein that other inhibitor for squalene synthetic enzyme comprises by P.Ortizde Montellano etc., at J.Med.Chem., 1977, 20The disclosed tetra-sodium terpenoid of 243-249, as by Corey and Volante, at J.Am.Chem.Soc., 1976,98, squalene (PSQ-PP) analogue before disclosed farnesyl diphosphate analogue A and the tetra-sodium among the 1291-1293, by McClard, R.W. etc., at J.A.C.S., 1987 109, the phosphinyl phosphonic acid esters of 5544 reports and by Capson, T.L., PhD dissertation, in June, 1987, Dept.Med.Chem.U of Utah, Abstract, Table of Contents, PP 16,17,40-43,48-51, the cyclopropane of Summary report.

Being suitable for as used herein, other hypolipidemic comprises, but be not limited to, fibric acid derivative, as fenofibrate, gemfibrozil, clofibrate, bezafibrate, Win-35833, S-8527 etc., probucol, and as in No. 3674836, United States Patent (USP) disclosed related compound, probucol and gemfibrozil are preferred, cholic acid chelating agent such as Colestyramine, colestipol and DEAE-Sephadex (Secholex , Policexide ), and lipostabil (Rhone-Poulenc), Eisai E-5050 (ethanolamine derivant that a kind of N-replaces), imanixil (HOE-402), tetrahydrochysene lipstatin (THL), istigmastanyl phosphorylcholine (SPC, Roche), amino cyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivatives), AC-233 (Sumitomo), Sandoz 58-035, American Cyanamid CL-277082 and CL-283546 (dibasic urea derivatives), nicotinic acid, acipimox, Acifran, Xin Meisu, right-aminosallcylic acid, acetylsalicylic acid, as be disclosed in poly-(diallyl methylamine) derivative in No. 4759923, the United States Patent (USP), as be disclosed in quaternary amine poly-(chlorination diallyl dimethyl ammonium) and ionene in No. 4027009, the United States Patent (USP) and the medicine of other known reduction serum cholesterol.

Other hypolipidemic can be for example to be disclosed in Drugs of the Future 24, the ACAT inhibitor among the 9-15 (1999), (Avasimibe); " ACAT inhibitor, Cl-1011 iseffective in the prevention and regression of aortic fatty streak area inhamsters ", Nicolosi etc., Atherosclerosis (Shannon, Irel). (1998), 137 (1), 77-85; " the pharmacology pattern of FCE 27677: a kind of new liver excretory selectivity with the lipoprotein through containing ApoB100 suppresses the active ACAT inhibitor of potent blood fat reducing of adjusting ", Ghiselli, Giancarlo, Cardiovasc.Drug Rev. (1998), 16 (1), 16-30; " RP73163: obtainable alkyl sulfinyl-diphenyl-imidazole ACAT inhibitor on a kind of biology ", Smith, C. etc., Bioorg.Med.Chem.Lett. (1996), 6 (1), 47-50; " ACAT inhibitor: reducing blood-fat in experimental animal and antiatherogenic active physiological mechanisms ", Krause etc., editor: Ruffolo, Robert R., Jr.; Hollinger, Mennfred A., Inflammation:Mediators Pathways (1995), 173-98, Publisher:CRC, BocaRaton, Fla.; " ACAT inhibitor: effective Antiatherosclerosis medicine ", Sliskovic etc., Curr.Med.Chem. (1994), 1 (3), 204-25; " as the acyl group-CoA that reduces the blood cholesterol medicine: cholesterol O-acyltransferase (ACAT) inhibitor.6. have fat and regulate active first water-soluble ACAT inhibitor.Acyl group-CoA: cholesterol acyltransferase (ACAT) inhibitor.7. a series of exploitations with N-phenyl-N '-[(1-benzyl ring amyl group) methyl] urea of the active replacement of enhanced reduction blood cholesterol "; Stout etc., Chemtracts:Org.Chem. (1995), 8 (6); 359-62, or TS-962 (Taisho Pharmaceutical Co.Ltd).

Hypolipidemic can be rise thing such as the MD-700 (TaishoPharmaceutical Co.Ltd) and the LY295427 (Eli Lilly) of LD2 receptor active.

Hypolipidemic can be cholesterol absorption inhibitor, the SCH48461 of preferred Schering-Plough and at Atherosclerosis 115,45-63 (1995) and J.Med.Chem.41, those disclosed inhibitor in 973 (1998).

Hypolipidemic can be as being disclosed in Drugs of the Future, 24, the ileum Na among the 425-430 (1999) ⁺/ cholic acid the protein inhibitor that cotransports.

Preferred hypolipidemic is Pravastatin, lovastatin, Simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin and rosuvastatin.

Above-mentioned United States Patent (USP) is attached to herein by reference.Amount of using and dosage should be as using its amount and dosage described in Physician ' s Desk Reference and/or the patent listed above.

Formula I compound of the present invention will with the weight ratio of hypolipidemic (if present) at about 500: 1 to about 1: 500, preferably to about 1: 100 scope, used at about 100: 1.

The dosage that gives must be according to patient's age, weight and disease, and route of administration, formulation and dosage regimen and required result are adjusted carefully.

The dosage of hypolipidemic and preparation will be as disclosed dosage and preparations in various patents discussed above and application.

Dosage and preparation (in the time of can using) for other hypolipidemic that will use will be as dosage and the preparations narrated in the Physician ' of latest edition s Desk Reference.

For oral administration, adopt the about 500mg of about 0.01mg/kg-, the MTP inhibitor of the amount in the about 100mg scope of preferably about 0.1mg-, can obtain satisfied effect at every day 1-4 time.

Preferred oral dosage form as tablet or capsule, will contain the about 500mg of the 1-that has an appointment, the about 400mg of preferably about 2-, the MTP inhibitor of the interior amount of 5-250mg scope more preferably from about, every day 1-4 time.

For oral administration, adopt HMG CoA reductase inhibitor, for example, Pravastatin, lovastatin, Simvastatin, atorvastatin, fluvastatin or cerivastatin, its dosage is as described in Physician ' the s Desk Reference, as with about 1-2000mg, the amount in the about 200mg scope of preferably about 4-is used, and can obtain satisfied effect.

Inhibitor for squalene synthetic enzyme can be with the about 2000mg of about 10mg-, and the dosage of the amount in the about 200mg scope of preferably about 25mg-uses.

Preferred oral dosage form as tablet or capsule, will contain the about 100mg of the 0.1-that has an appointment, the about 80mg of preferably about 5-, more preferably from about the HMG CoA reductase inhibitor of the amount of the about 40mg of 10-.

Preferred oral dosage form as tablet or capsule, will contain the about 500mg of the 10-that has an appointment, the inhibitor for squalene synthetic enzyme of preferably about 25-200mg amount.

Other hypolipidemic also can be a lipoxygenase inhibitor, comprise that 15-lipoxidase (15-LO) inhibitor is as being disclosed in the benzimidizole derivatives among the WO 97/12615, as be disclosed in 15-LO inhibitor among the WO 97/12613, be disclosed in 96/38144 isothiazolones (isothiazolones) and as by Sendobry etc. " the 15-lipoxygenase inhibitor with the high selectivity of the remarkable antioxidant properties of shortage weakens food-induced atherosclerosis in rabbit ", Brit.J.Pharmacology (1997) 120,1199-1206, with Cornicelli etc., " 15-lipoxidase and restraining effect thereof: a kind of therapeutical agent of new vascular disease ", CurrentPharmaceutical Design, 1999,5, disclosed 15-LO inhibitor among the 11-20.

Formula I compound and hypolipidemic can use together or take with the oral dosage form that separates in the identical time with same oral dosage form.

Above-mentioned composition can be with aforesaid formulation, and with single dose or divided dose, give every day for 1-4 time.Giving the composition of patient's low dosage during beginning, be enlarged to the composition of high dosage later on gradually, may be rational.

Preferred hypolipidemic is Pravastatin, Simvastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin and rosuvastatin.

The therapeutical agent of other type of using when the SGLT2 inhibitor that can choose wantonly with formula I is 1,2,3 or during more kinds of anti-obesity medicine, it can comprise 'beta '3 adrenergic agonists, lipase inhibitor, thrombotonin (and Dopamine HCL) reuptake inhibitor, Tiroidina beta receptor medicine, anoretics, NPY antagonist, Leptin analogue and/or MC4 agonist.

It is known as be disclosed in β 3 agonists in No. 5541204,5770615,5491134,5776983 and 5488064, the United States Patent (USP), preferred AJ9677, L750355 and CP331648 to choose the 'beta '3 adrenergic agonists of uniting use with formula I compound wantonly and can be AJ9677 (Takeda/Dainippon), L750355 (Merck) or CP331648 (Pfizer) or other.

Can choose the lipase inhibitor of uniting use with formula I compound wantonly can be orlistat or ATL-962 (Alizyme), preferred orlistat.

Can choose thrombotonin (and Dopamine HCL) reuptake inhibitor of uniting use with formula I compound wantonly can be sibutramine, topiramate (Johnson ﹠amp; Johnson) or axokine (Regeneron), preferred sibutramine and topiramate.

Can choose the Tiroidina beta receptor compound of uniting use with formula I compound wantonly can be as being disclosed in WO97/21993 (U.Cal SF), WO99/00353 (KaroBio) and GB98/284425 (KaroBio), the compound in the preferred KaroBio application.

Can choose the anoretics of uniting use with formula I compound wantonly can be Dextrofenfluramine, phentermine, Phenylpropanolamine or Mazindol, preferred Dextrofenfluramine.

Above-mentioned various antiadipositas drugs can use with same formulation or the different formulation of generally knowing with this area or PDR, dosage and therapeutic regimen with formula I compound.

The example of uniting anti--thrombocyte medicine of use be can choose wantonly and ReoPro, ticlopidine, eptifibatide, Dipyridamole, acetylsalicylic acid, anagrelide, tirofiban and/or clopidogrel comprised with The compounds of this invention.

The example of uniting anti--hypertension drug of use be can choose wantonly and ACE inhibitor, calcium antagonist, alpha block agent, diuretic(s), central action agent, Angiotensin-II antagonist, beta blocker and vasopeptidase (vasopeptidase) inhibitor comprised with The compounds of this invention.

The example of ACE inhibitor comprises that lisinopril, enalapril, quinapril, benazepril, fosinopril, Ramipril, captopril, enalapril draw, moexipril, Trolapril and perindopril; The example of calcium antagonist comprises amlodipine, diltiazem , nifedipine, verapamil, felodipine, nisoldipine, Isrodipine and nicardipine; The example of alpha block agent comprises terazosin, Doxazosin and Prazosin; The example of diuretic(s) comprises hydrochlorothiazide, torasemide, Furosemide, spironolactone and indapamide; The example of cental system agent comprises clonidine and guanfacine; The example of Angiotensin-II antagonist comprises losartan, valsartan, irbesartan, candesartan and telmisartan; The example of beta blocker comprises Mi Tuoluoer, Proprasylyte, atenolol USP 23, carvedilol and sotalol; And the example of vasopeptidase inhibitors comprises omapatrilat and gemopatrilat.

In implementing method of the present invention, use is contained medicinal compositions with pharmaceutically acceptable carrier or thinner bonded structure I compound, said composition can contain or not contain another kind of antidiabetic medicine and/or lipidemia medicine, or the therapeutical agent of other type.Use conventional solid or liquid vehicle or thinner and certain type the medicinal additive that is suitable for required administering mode, can prepare medicinal compositions.This compound can be with for example form of tablet, capsule, granule or powder, by oral route gives mammal, comprise people, monkey, dog etc., perhaps they can give through the parenteral approach with the form of injection formulations, and perhaps they can via intranasal application or give with the form through the skin patch.For the adult, dosage is preferably at 10-2000mg/ between day, and it can single dose or with the form of the dosage that separates, gives for 1-4 time every day.

By aseptic technique, the compound of 250mg structure I is placed phial, freeze-drying and sealing under aseptic condition prepare general injection formulations.For ease of using, the content in the phial is mixed with 2ml physiological saline, with the preparation injection formulations.

The SGLT2 inhibitor activity of The compounds of this invention can be by using mensuration systems measurement as described below.

The active mensuration of SGLT2

Adopt standard molecular biological technique, by reverse transcription and amplification, from the mRNA sequence (GenBank #M95549) of people's kidney mRNA human cloning SGLT2.The cDNA sequence is stabilized the ground transfection to Chinese hamster ovary celI, basic as (1994) such as Ryan as described in, carry out the active mensuration of SGLT2 to cloning thing.Substantially as described in Ryan etc., but do following modification, in the clone of clonal selection, carried out the active inhibiting evaluation of SGLT2.On the 96-orifice plate, in F-12 nutritional blend (Ham ' s F-12), 10% foetal calf serum, 300 μ g/ml Geneticins and penicillin-Streptomycin sulphate, make cell growth 2-4 days, to reach every hole 75000 or 30000 cells.After converging, with 10mM Hepes/Tris (pH 7.4), twice of 137mM N-methyl D-glycosamine, 5.4mM Repone K, 2.8mM calcium chloride, 1.2mM sal epsom washed cell.In 37 ℃, make cell and 10 μ M[then ¹⁴C] AMG and 10 μ M inhibitor (final DMSO=0.5%) in 10mM Hepes/Tris (pH 7.4), hatched 1.5 hours in 137mM sodium-chlor, 5.4mM Repone K, 2.8mM calcium chloride, the 1.2mM sal epsom.Measure thing with the ice-cold 1 * PBS quencher picked-up that contains the 0.5mM phlorizin, use 0.1% dissolution of sodium hydroxide cell then.After adding the MicroScint scintillating liquid, made the cell jolting 1 hour, then on the TopCount scintillometer to [ ¹⁴C] AMG is quantitative.Controlled trial can be carried out under situation about having with non-sodium chloride.For EC ₅₀The mensuration of value in suitable responding range, with 2log at interval, adopts 10 inhibitor concentration, on assay plate triplicate plate is averaged.

Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA and Torok-Storb be B.1994.HK-2: a kind of immortalization proximal tubule epithelial cell line that derives from the normal adult kidney.Kidney International 45：48-57。

The embodiment that below works represents the preferred embodiments of the invention.All temperature are all with degree centigrade representing, except as otherwise noted.

Embodiment 1

A.3-bromo-4 '-ethyl diphenyl-carbinol (benzylhydrol)

Under argon atmospher, with dry magnesium chips (4.4g 0.178mol) stirs and to spend the night, and adds the 100ml anhydrous diethyl ether subsequently, then be added in 1 hour right-bromo ethyl phenenyl in the 20ml ether (22g, 0.119mol).(under the situation that reaction does not begin, adding the 0.5ml glycol dibromide).After stirring is spent the night, slowly be added in the 20ml ether between-bromobenzaldehyde (11g, 0.06mol).By light solution 4-6 hour of HPLC monitoring formation, finish to determine reaction.After the saturated aqueous ammonium chloride quencher, with ethyl acetate extraction (3X) reactant.Organic layer with the salt water washing merges through dried over sodium sulfate, concentrates with rotatory evaporator.The yellow oil that produces with the nonpolar impurity of 5% ethyl acetate/hexane wash-out, with 7-9% ethyl acetate/hexane wash-out, obtains 3-bromo-4 '-ethyl diphenyl-carbinol of 12.4g (71%) through silica gel column chromatography, is faint yellow oily thing.

B.3-bromo-4 '-ethyl ditan

(12.4g 0.0426mol) adds BF in the stirred solution of 120ml MeCN to the 3-of-30 ℃ part A bromo-4 '-ethyl diphenyl-carbinol ₃Et ₂(6.04g 0.0426mol), then adds Et to O ₃SiH (9.9g, 0.852mol).After 1 hour, dark reactant slowly is warmed to-5 ℃ in-30 ℃ of stirrings.When the tlc monitoring is finished, should reaction by adding the quencher of unsaturated carbonate aqueous solutions of potassium.After adding 100ml water, with this mixture of ether extraction 3 times.With the organic layer of salt water washing merging, through dried over sodium sulfate.After concentrating with rotatory evaporator, obtain 3-the bromo-4 '-ethyl ditan (11.17g, 95%) into faint yellow oily thing, it need not to be further purified and uses.

Under argon atmospher, (10.9g 0.04mol) adds the hexane solution of 25.7ml 1.7M tert-butyl lithium in the stirred solution of the anhydrous THF of 100ml with 3-bromo-4 '-ethyl ditan of the part B of 20 fens clockwise-78 ℃.After 1 hour, with being added in 2,3,4 among the 30ml THF in 15 minutes, 6-four-O-benzyl-β-maltonic acid lactone (23.5g, 0.0437mol).Stir these solution 1 hour in-78 ℃, use the saturated aqueous ammonium chloride quencher then.After being warmed to 20 ℃, with this reactant of 2 times of dilutions of ethyl acetate, order water and salt water washing then.After concentrating through dried over sodium sulfate and with rotatory evaporator, obtain the required title lactol into the 29.2g of colourless soup compound, it need not to be further purified and is used for subsequently step.

(29.1g 0.04mol) adds BF in the stirred solution of 100ml MeCN to the lactol of-30 ℃ portion C ₃Et ₂(5.62g 0.04mol), then adds Et to O ₃SiH (9.21g, 0.08mol).After 2 hours, when tlc shows that reaction will be finished, add the unsaturated carbonate aqueous solutions of potassium, stirred this suspension 1 hour, water and ether dilution then in 20 ℃.Derive from the organic layer of the merging of 3 parts of ether extracts with the salt water washing,, after concentrating with rotatory evaporator, obtain the faint yellow soup compound of 28.3g through dried over sodium sulfate.Through silica gel column chromatography, with the nonpolar impurity of 5% ethyl acetate/hexane wash-out, then wash-out moves slower required β anomer, is the α anomer then.By grind (triterating) with hexane or from ethanol recrystallization, can select single step purification to be rich in the flow point of β anomer, obtain the required title β four-O-benzyl C-glucoside of 6g.(note working as Et ₃When SiH is reductive agent, obtains 5: 1 beta/alpha anomer mixture, and work as iPr ₃When SiH is replaced, obtain 30: 1 mixture).

Under 1 normal atmosphere hydrogen, will contain 10%Pd (OH) ₂Four-O-benzyl C-glucoside of the part D of/C (0.35g) (2.4g, spend the night by ethyl acetate 3.35mmol) (100ml) solution stirring.After HPLC showed that this reaction is finished, filtering catalyst except that desolvating, obtained the required β C-glucoside (92%) of 1.1g with rotatory evaporator, is white crystalline solid.The HPLC retention time: 7.04 minutes, 100% purity, YMC S5 C-18 4.6 * 50mm post 2.5ml/ minute, detects in 220nM; 0-100%B gradient liquid 8 minutes kept 5 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(500MHz，CD ₃OD)δ7.27(s，1H)，7.23(d，2H，J＝4.95Hz)，7.1-7.0(m，5H)，4.08(d，1H，J＝9.3Hz)，3.91(s，2H)，3.9(dd，1H，J＝2.2，11Hz)，3.68(dd，1H，J＝5.5，11.5Hz)，3.5-3.35(m，4H)，2.57(q，2H，J＝7.2Hz)，1.18(t，3H，J＝7.2Hz)。

¹³C NMR(125MHz，CD ₃OD)δ143，142.8，141，140，129.9，129.6，129.5，129.1，128.8，126.7，83.8，82.3，79.9，76.4，72.0，63.2，42.5，29.4，16.2。

C ₂₁H ₂₆O ₅The analytical calculation value [M+NH4] 376 of LC-MS; Measured value 376.

Embodiment 2

A.3-bromo-4 '-methoxyl group diphenyl-carbinol

Under argon atmospher, with between 10 fens clockwise-78 ℃-(70.9g 0.3mol) adds the hexane solution of 117ml 2.56M n-Butyl Lithium (0.3mol) to dibromobenzene in the stirred solution of the anhydrous THF of 200ml.After 30 minutes, be added in 20 minutes right-methoxybenzaldehyde among the 50ml THF (27.2g, 0.02mol).In-78 ℃ of these solution of stirring 1 hour (finishing), use the saturated aqueous ammonium chloride quencher then through the tlc monitoring.After being warmed to 20 ℃, with this reactant of 2 times of dilutions of ethyl acetate, order water and salt water washing then.After dried over sodium sulfate, concentrate with rotatory evaporator, obtain 103g 3-bromo-4 '-methoxyl group diphenyl-carbinol into yellow oil, it need not to be further purified and is used for subsequently step.

B.3-bromo-4 '-methoxyl group ditan

(103g 0.2mol) adds Et in the stirred solution of 300ml MeCN to the crude product 3-of-40 ℃ part A bromo-4 '-methoxyl group diphenyl-carbinol ₃(64ml 0.4mol), then adds BF to SiH ₃Et ₂O (27.7g, 0.2mol).When the tlc monitoring is finished, should reaction by adding unsaturated carbonate aqueous solutions of potassium (25ml) quencher.After adding 100ml water, with this mixture of ethyl acetate extraction 3 times.With the organic layer of salt water washing merging, through dried over sodium sulfate.After concentrating with rotatory evaporator, crude product title compound 3-bromo-4 '-methoxyl group ditan (92g) with 9% ethyl acetate/hexane wash-out, obtains the 17g clean product through silica gel column chromatography, obtains impure flow point subsequently.

Under argon atmospher, (9.6g 0.035mol) adds the hexane solution of 14ml 2.5M n-Butyl Lithium in the stirred solution of the anhydrous THF of 50ml with 3-bromo-4 '-methoxyl group ditan of the part B of 5 fens clockwise-78 ℃.Stir after 30 minutes, with being added in 2,3,4 among the 20ml THF in 10 minutes, 6-four-O-benzyl-β-maltonic acid lactone (12.5g, 0.023mol).Stirred these solution 1 hour in-78 ℃, tlc analyzed this reaction of indication and finished this moment.After saturated aqueous ammonium chloride (25ml) quencher, be warmed to 20 ℃, (200ml) dilutes this reactant with ethyl acetate.Order water and salt water washing organic layer.After concentrating through dried over sodium sulfate and with rotatory evaporator, required title lactol with 12.5% ethyl acetate/hexane wash-out, obtains the lactol of 8.1g＞90% through silica gel column chromatography, obtains the lactol of 9.7g＞80% purity subsequently.

(7.8g 0.019mol) adds Et in the stirred solution of 100ml MeCN to the lactol of-40 ℃ portion C ₃(3.42ml 0.04mol), then adds BF to SiH ₃Et ₂O (1.37ml, 0.02mol).After 1 hour, when tlc shows that reaction will be finished, add unsaturated carbonate aqueous solutions of potassium (10ml), stirred these suspension 1 hour in 20 ℃, use ethyl acetate extraction then 3 times.The organic layer that water and salt water washing merge through dried over sodium sulfate, after concentrating with rotatory evaporator, obtains the 8g crude product.Through silica gel column chromatography, with the nonpolar impurity of 5% ethyl acetate/hexane wash-out, then obtain the purified title β of 0.92g-four-O-benzyl C-glucoside, obtain the mixture that 6.5g contains two kinds of anomers subsequently.

Under 1 normal atmosphere hydrogen, in ethyl acetate (the compound 12.5ml of every gram part D), through 10%Pd (OH) ₂(2% weight) respectively above the hydrogenation part D compound of two parts spend the night.Filter and remove desolvate after, with YMC S10 reversed-phase column, through the hydroformylation product solution of preparation property HPLC purifying mixing portion.Merge material and obtain the pure β anomer of 1.85g, be white solid.

The HPLC retention time: 6.04 minutes, Zorbax C-18 4.6 * 75mm post, the 2.5ml/ clock detects in 220nM; 0-100%B gradient liquid 8 minutes kept 3 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(400MHz，CD ₃OD)δ7.28(s，1H)，7.24(d，2H，J＝3Hz)，7.09(m，3H)，6.79(d，2H，J＝7Hz)，4.08(d，1H，J＝8.8Hz)，3.88(s，2H)，3.75(d，1H，J＝12Hz)，3.73(s，3H)，3.65(dd，1H，J＝12，3Hz)，3.4(m，4H)。

¹³C NMR(100MHz，CD ₃OD)δ158.6，142.1，140.2，133.8，130.0，128.7，128.6，128.3，125.8，82.9，81.3，79.0，75.5，71.1，62.5，55.1，41.1。

C ₂₀H ₂₄O ₆The analytical calculation value [M-H] 359 of LC-MS; Measured value 359.

Embodiment 3

Under argon atmospher, with between 10 fens clockwise-78 ℃-(12.6g 53mmol) adds molten night of hexane of 20ml 2.56M n-Butyl Lithium (51mmol) to dibromobenzene in the stirred solution of the anhydrous THF of 50ml.After 40 minutes, with being added in 2,3,4 among the 30ml THF in 15 minutes, 6-four-O-benzyl-β-maltonic acid lactone (12g, 22mol).In-78 ℃ of these solution of stirring 1 hour (finishing), use saturated aqueous ammonium chloride (40ml) quencher then through the tlc monitoring.After being warmed to 20 ℃, with this reactant of 2 times of dilutions of ethyl acetate, order water and salt water washing then.After concentrating through dried over sodium sulfate and with rotatory evaporator, obtain the 20g crude product title lactol into oily matter, it need not to be further purified and is used for subsequently step.

(20g 0.2mol) adds Et in the stirred solution of 60ml MeCN to the crude product lactol of-45 ℃ part A ₃SiH (7.8ml, 45mmol), then with 20 minutes slow BF that add ₃Et ₂O (4.2ml, 22mmol).After 1 hour, when tlc shows that reaction is finished, add unsaturated carbonate aqueous solutions of potassium (25ml) quencher reactant, with this mixture of ethyl acetate extraction 3 times.Organic layer with the salt water washing merges through dried over sodium sulfate, concentrates with rotatory evaporator.Grind the oily matter that obtains with the 50ml hexane, leave standstill 1 hour postprecipitation and go out solid.Filter to collect this material, with cold hexane wash twice, obtain after air-dry the required title β of 8.9g--bromo phenyl-C-glucoside.

Under argon atmospher, with the β of part B--bromo phenyl C-glucoside (1.36g, 2mmol), four (triphenyl phosphines) close palladium (70mg, 0.06mmol) (2.724g, 6mmol) solution in dry toluene (10ml) heated while stirring 15 hours in 80 ℃ with six dibutyltin dilaurate alkane.After removing toluene with rotatory evaporator, residue is through silica gel column chromatography, with 12: 1 required title aryl stannanes (761mg) of ethyl acetate/hexane wash-out, add the blended part, after it is crossed post for the second time, obtain the purified title stannane of other 92mg, total recovery 48%, then gather in the crops the β of the raw material part B of 230mg--bromo phenyl-C-glucoside.

Under argon atmospher, with the stannane of part E (2.66g, 3mmol), right-trifluoro-methoxybenzyl chlorine (1.04g, 6mmol) and four (triphenyl phosphines) close palladium (100mg, mixture 0.09mmol) refluxed 15 hours in THF (1ml).After removing THF with rotatory evaporator, residue with 10: 1 hexane/ethyl acetate wash-outs, obtains the required title of 1.3g four benzyl oxides through silica gel column chromatography.

Under 1 normal atmosphere hydrogen, four benzyl oxides by stirring 295mg part D in ethyl acetate (3ml) and palladium hydroxide (15mg) 15 hours reach the conversion to final free glucoside.After filtration, after preparation property HPLC and removing desolvates, isolate title product (104mg).

The HPLC retention time: 7.21 minutes, Zorbax C-18 4.6 * 75mm post 2.5ml/ minute, detected in 220nM; 0-100%B gradient liquid 8 minutes kept 3 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(400MHz，CD ₃OD)δ7.3(m，5H)，7.15(m，3H)，4.10(d，1H，J＝8.8Hz)，3.99(s，2H)，3.9(d，1H，J＝12Hz)，3.7(dd，1H，J＝12，3Hz)，3.4(m，4H)。

C ₂₀H ₂₁F ₃O ₆LC-MS[M-H] analytical calculation value 413; Measured value 413.

Embodiment 4

Under argon atmospher, with the β of embodiment 3 part B--bromo phenyl-C-glucoside (3.0g, 4.41mmol), four (triphenyl phosphines) close palladium (153mg, 0.13mmol) and six dibutyltin dilaurate alkane (6.0g, 13.2mmol) mixture in dry toluene (5ml) heated while stirring 3 hours in 88 ℃, analyze the reaction of indication 90% through tlc and finish.After 5 hours, stop this reaction altogether.After removing toluene with rotatory evaporator, residue with 1: 8 ethyl acetate/hexane wash-out, obtains the required aryl stannane of 2.95g through silica gel column chromatography.

Under argon atmospher, with the stannane of part A (2.66g, 3mmol), right-the methylthio group benzyl chloride (1.04mg, 6.0mmol) and four (triphenyl phosphines) close palladium (100mg, mixture 0.09mmol) refluxed 15 hours in THF (5ml).After removing THF with rotatory evaporator, residue with 6: 1 hexane/ethyl acetate wash-outs, obtains the required title four-O-benzylic ether of 1.2g through silica gel column chromatography, obtains title four-O-benzylic ether that 600mg contains triphenyl phosphine subsequently.

Under argon atmospher, (6ml, (295mg was 0.4mmol) in the stirred solution in methylene dichloride (0.25ml) 8mmol) to join-78 ℃ part B tetrabenzyl ether with 1M boron trichloride/methylene dichloride with 5 minutes.After 30 minutes, when tlc shows that reaction is finished, add 2: 1 methylene dichloride/PhMe of 30ml, then add 2ml methyl alcohol.With rotatory evaporator its volume is reduced half, add 10ml methyl alcohol.After repeating this process 3 times, remove all volatile matters under the vacuum.Residue with 5% ethanol/methylene wash-out, obtains the required glucoside of 143mg, purity 90% through silica gel column chromatography.This material is further purified through anti-phase preparation HPLC, obtains the required final glucoside of 104mg.

The HPLC retention time: 6.69 minutes, Zorbax C-18 4.6 * 75mm post 2.5ml/ minute, detected in 220nM; 0-100%B gradient liquid 8 minutes kept 3 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(400MHz，CD ₃OD)δ7.27(s，1H)，7.25(d，2H，J＝2Hz)，7.15(m，5H)，4.09(d，1H，J＝8.8Hz)，3.92(s，2H)，3.86(d，1H，J＝12Hz)，3.68(dd，1H，J＝12，3Hz)，3.4(m，4H)，2.43(s，3H)。

C ₂₀H ₂₄O ₆S LC-MS[M-H] analytical calculation value 375; Measured value 375.

Embodiment 5

Under argon atmospher, to 60% sodium hydride (180mg, 4.5mmol) add in the stirred suspension in THF (7ml) the 2-bromophenol (350 μ l, 3mmol).Stir after 15 minutes, this reactant is cooled to-78 ℃, and dropping 1.4M tert-butyl lithium/hexane (2.36ml, 3.3mmol).After 10 minutes, by conduit with this solution be transferred to-78 ℃ 2,3,4, (1.62g is in the stirred solution of THF 3.0mmol) (5ml) for 6-four-O-benzyl-β-maltonic acid lactone.After 15 minutes, should react, and make then to be warmed to 20 ℃, add the 200ml ethyl acetate this moment by slow adding saturated ammonium chloride/water quencher.Water and salt solution wash organic layer in proper order, through dried over mgso and concentrated.Through silica gel column chromatography,, obtain the required title lactol of 390mg with 3: 1 hexane/ethyl acetate wash-outs.

At-30 ℃, (add Et among the 390mg, 3: 1 the mixture (4ml) of MeCN/ methylene dichloride 0.62mmol) to the lactol that contains part A that stirs ₃SiH (197 μ l, 1.23mmol) and BF ₃Et ₂O (78 μ l, 0.62mmol).After 1 hour, by adding 1ml unsaturated carbonate potassium solution quencher reaction, be warmed to 20 ℃, with the dilution of 100ml ethyl acetate.Water and salt solution wash organic layer in proper order, through dried over mgso and concentrated.Through silica gel column chromatography,, obtain the C-glucoside of the required title phenol of 269mg with 3: 1 hexane/ethyl acetate wash-outs.

Under argon atmospher, to the phenol of part B (add among the 139mg, PhMe solution (1.1ml) 0.22mmol) 60% sodium hydride (11mg, 0.27mmol).After 10 minutes, will for solid 4-methyl-benzyl bromine (46mg 0.25mmol) joins in this blue solution, then with its in 80 ℃ the heating 3.5 hours, until finishing through the tlc analytical reaction.After cooling then adds aqueous ammonium chloride solution, with ethyl acetate diluting reaction thing.Water and salt solution wash organic layer in proper order, through dried over mgso and concentrated.Through silica gel column chromatography,, obtain the required title four-O-benzyl glucoside of 71mg with 5: 1 hexane/ethyl acetate wash-outs.

Subsequently, under 1 normal atmosphere hydrogen, in methyl alcohol, four-O-benzyl glucoside through Pd/C hydrogenolysis portion C, obtain final title product, it is passed through preparation property HPLC purifying with the C18 reversed-phase column, use 45-90% methanol gradient liquid wash-out 10 minutes, obtain required β-C-glucoside (2mg).

The HPLC retention time: 6.754 minutes, 100% purity, YMC S3 ODS 4.6 * 50mm 2.5ml/ minute, detects in 220nM; 0-100%B gradient liquid 8 minutes kept 5 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(500MHz，CD ₃OD)δ7.15(dd，1H，J＝1.1，7.7Hz)，7.07(d，2H，J＝8.3Hz)，7.02(d，2H，J＝8.3Hz)，6.96(dd，1H，J＝1.2，7.7Hz)，6.77(t，1H，J＝7.7Hz)，4.44(d，1H，J＝8.8Hz)，3.89(s，2H)，3.87(d，1H，J＝2.2Hz)，3.75(dd，1H，J＝4.9，12.1)，3.49-3.41(m，4H)，2.26(s，3H)。

C ₂₀H ₂₄O ₆LC-MS[M+H] analytical calculation value 361; Measured value 361.

Embodiment 6

A. right-the chloro methyl acetanilide

Under-20 ℃, argon atmospher, to right-chloro methyl benzoyl chloride (390mg, 2.06mmol) add in the stirred solution in 8ml THF tributylphosphine (406mg, 2.29mmol).After 20 minutes, the disposable 0.7ml 3M methylmagnesium-bromide (2.1mmol) that is added in the ether generates red solution in-20 ℃ to-15 ℃ yellow solutions that stir generation, and it became orange subsequently in 10 minutes.Should reaction by adding the quencher of 1N aqueous hydrochloric acid.Behind the dilute with water,, wash with water, then through dried over sodium sulfate with this mixture of ethyl acetate extraction 3 times.With removing residue that volatile matter obtains through silica gel column chromatography, with 5% ethyl acetate/hexane wash-out, obtain 171mg (50%) right-the chloro methyl acetanilide.

Under 70 ℃, argon atmospher, stannane (300mg with embodiment 3 portion C, 0.33mmol), right-chloro methyl acetanilide (114mg, 0.66mmol), four (triphenyl phosphines) close palladium (20mg, 0.09mmol), triphenyl phosphine oxide (180mg, 0.65mmol), (75mg, mixture 0.55mmol) heated 16 hours in THF (0.3ml) salt of wormwood.After removing THF with rotatory evaporator, residue is through silica gel column chromatography, with 20: 1-10: 1 hexane/ethyl acetate wash-out obtains required tetrabenzyl ether (170mg, 70%).

Under argon atmospher, (60mg, methylene dichloride 0.08mmol) (5ml) solution is cooled to-78 ℃, adds the dichloromethane solution of 0.8ml 1M boron trichloride then with the tetrabenzyl ether of part B., after 1 hour second part of 0.8ml 1M boron trichloride joined in the reactant of this stirring in-78 ℃ of stirrings.After the second hour, add 0.5ml PhMe, then drip the methyl alcohol of 0.5ml.Remove volatile matter with rotatory evaporator; After adding 2: 1 mixture of 3ml methylene chloride, repeat this process.The residue that produces with 5% methanol/ethyl acetate wash-out, obtains 20mg tetrol end product, yield 67% through silica gel column chromatography.

The HPLC retention time: 2.35 minutes, 100% purity, YMC S3 ODS 4.6 * 50mm 2.5ml/ minute, detects in 220nM; 0-100%B gradient liquid 4 minutes kept 4 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(500MHz，CD ₃OD)δ7.88(d，2H)，7.27-7.34(m，5H)，7.13(d，1H)，4.09(d，1H)，4.03(s，2H)，3.85(d，1H)，3.68(dd，1H)，3.35-3.48(m，4H)，2.55(s，3H)

¹³C NMR (500MHz, CD ₃OD) δ 200.3,148.8,141.4,141.2,136.3,130.2,129.7,129.6,129.3,127.0,83.6,82.2,79.8,76.4,71.9,63.1,42.7,26.6C ₂₁H ₂₄O ₆The analytical calculation value 390.2 of LC-MS (M+NH4+); Measured value 390.2.

Embodiment 7

With the end product of embodiment 6 (15mg, 0.04mmol) stirred solution in 5ml ethanol is cooled to-20 ℃, to wherein add sodium borohydride (5mg, 0.13mmol).After 20 minutes, finish through the tlc analytical reaction, should reaction with several saturated aqueous ammonium chloride quenchers.After removing volatile matter, residue with 5% methanol/ethyl acetate wash-out, obtains the required product of 10mg (67%) through silica gel column chromatography.

The HPLC retention time: 5.2 minutes, 100% purity, YMC S3 ODS 4.6 * 50mm 2.5ml/ minute, detects in 220nm; 0-100%B gradient liquid 8 minutes kept 5 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(500MHz，CD ₃OD)δ7.21-7.32(m，5H)，7.16(d，2H)，7.10-7.11(m，1H)，4.77(q，1H)，4.08(d，1H)，3.94(s，2H)，3.86(dd，1H)，3.68(dd，1H)，3.34-3.48(m，4H)，1.40(d，3H)

¹³C NMR (500MHz, CD ₃OD): δ 145.2,142.5,141.5,140.9,129.8,129.6,129.5,129.2,126.7,126.6,83.7,82.2,79.8,76.4,72.0,63.2,42.5,25.5C ₂₁H ₂₆O ₆The analytical calculation value 392.2 of LC-MS (M+NH4+); Measured value 392.1.

Embodiment 8

A.5-bromo-2-tolyl acid

In 0 ℃, with neighbour-tolyl acid (28g, 206mmol), iron powder (0.74g, 13mmol) and Br ₂(42g, mixture 260mmol) stirred 2 hours.This reaction this moment has been carried out about 40%, and usefulness 25ml methylene dichloride dilutes, and stirs with facility.In 45 ℃ this reactant was heated 16 hours then, finish to impel reaction.After the cooling, dilute this reactant, with 10% sodium bisulfite washing 2 times, with salt water washing 1 time, then through dried over sodium sulfate with methylene dichloride.After removing volatile matter, make to contain 5-bromomethyl phenylformic acid: the residue of benzoic 2: 1 mixtures of 3-bromomethyl recrystallization from 95% ethanol obtains 14.4g 5-bromo-2-tolyl acid.

B.5-bromo-2-methyl-4 '-methoxyl group benzophenone

(1.29g 6mmol) adds 2 DMF in 12ml contains stirred suspension in the methylene dichloride of oxalyl chloride (8mmol) to 5-bromo-2-tolyl acid.As soon as the violent release of gas stops, stirring this reactant 6 hours, remove volatile matter with rotatory evaporator then.After crude product 5-bromo-2-methyl benzoyl chloride is dissolved in the 15ml dithiocarbonic anhydride, stirred mixture is cooled to 4 ℃, add then methyl-phenoxide (0.7g, 6.6mmol), then add aluminum chloride (1.7g, 12mmol).Be warmed to 20 ℃ after 1 hour, this reactant was stirred 15 hours, use 1N HCl quencher then.Subsequently, dilute this suspension, be stirred to all solids and be dissolved in the solution with 50ml water.With this mixture of ethyl acetate extraction 3 times.The organic layer that merges with each washing of 1N HCl, water, sodium bicarbonate aqueous solution and salt solution 1 time is through dried over sodium sulfate.After removing volatile matter, make brown solid recrystallization from 95% ethanol of generation, obtain 1.6g 5-bromo-2-methyl-4 '-methoxyl group benzophenone.

C.5-bromo-2-methyl-4 '-methoxyl group ditan

With Et ₃SiH (2.5ml, 15.5mmol), BF ₃Et ₂(1.3ml, 10mmol) (1.6g, 5.25mmol) solution in 1: 4 mixture of 11ml methylene dichloride/MeCN spends the night in 20 ℃ of stirrings O with 5-bromo-2-methyl-4 '-methoxyl group benzophenone.Owing to show through HPLC, have 5% raw ketone to exist, with this solution be heated to 40 ℃ 1 hour, use 10% sodium hydroxide quencher then.Behind the dilute with water, with this reactant of ethyl acetate extraction 3 times.Wash the organic layer 2 times of merging with water, with salt water washing 1 time, then through dried over sodium sulfate.After removing volatile matter, residue is used the hexane wash-out through silica gel column chromatography, obtains 5-bromo-2-methyl-the 4 '-methoxyl group ditan (1.4g, 95%) into colorless oil.

Under argon atmospher, to the 5-of-78 ℃ portion C bromo-2-methyl-4 '-methoxyl group ditan (0.43g, 1.5mmol) hexane solution of dropping 0.9ml 1.8M n-Butyl Lithium in the stirred solution of the anhydrous THF of 7ml.After 2 hours, with being added in 2,3,4 among the 3ml THF in 1 minute, 6-four-O-benzyl-β-maltonic acid lactone (0.88g, 1.6mmol).Stir these solution 2 hours in-78 ℃, use the saturated aqueous ammonium chloride quencher then.After being warmed to 20 ℃, this reactant of 2 times of dilutions of water is used ethyl acetate extraction 3 times then.With the ethyl acetate part of salt water washing merging, through dried over sodium sulfate.After concentrating with rotatory evaporator, obtain the required title lactol into colourless soup compound, it need not to be further purified and is used for subsequently step.

(1.1g 1.47mmol) adds iPr in the stirred solution of 10ml MeCN to the lactol of-30 ℃ part D ₃(0.7g 4.5mmol), then adds BF to SiH ₃Et ₂O (0.38g, 2.6mmol).In-40 ℃ to-30 ℃ after 3 hours, tlc shows that reaction finishes.Add the unsaturated carbonate aqueous solutions of potassium, stirred this suspension 1 hour, water and ethyl acetate dilution then in 20 ℃.With the organic layer that derives from 3 parts of ethyl acetate extracts of salt water washing merging, through dried over sodium sulfate.Concentrate with rotatory evaporator, obtain the faint yellow soup compound of 1.2g.Through silica gel column chromatography,, then obtain required β C-aryl glucoside (0.54g) with the nonpolar impurity of 10% ethyl acetate/hexane wash-out.

Under 1 normal atmosphere hydrogen, (515mg 0.7mmol) is containing 10%Pd (OH) with four-O-benzyl C-glucoside of part E ₂Solution stirring in the ethyl acetate (10ml) of/C (80mg) is spent the night.After HPLC showed that reaction is finished, filtering catalyst except that desolvating, obtained white glass shape solid with rotatory evaporator, uses C ₁₈Reversed-phase column is further purified it through preparation property HPLC, obtaining 220mg is the required β C-glucoside of colourless soup compound.

The HPLC retention time: 6.43 minutes, 100% purity, YMC S5 C-18 4.6 * 50mm post 2.5ml/ minute, detects in 220nM; 0-100%B gradient liquid 8 minutes kept 5 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(500MHz，CD ₃OD)δ7.20(s，1H)，7.18(d，1H，J＝7Hz)，7.11(d，1H，J＝7Hz)，6.89(ABq，4H)，4.07(d，1H，J＝9Hz)，3.90(s，2H)，3.87(m，1H)，3.70(s，3H)，3.68(dd，1H)，3.48-3.30(m，4H)，2.16(s，3H)。

¹³C NMR(125MHz，CD ₃OD)δ159.3，140.3，138.3，137.4，133.7，131.0，130.8，130.6，126.9，114.7，83.5，82.1，79.8，76.3，71.9，63.1，55.6，59.6，19.5。

C ₂₁H ₂₆O ₆LC-MS[M-H] analytical calculation value 373; Measured value 373.

Embodiment 9

A.5-bromo-2-methyl-4 '-hydroxy diphenyl methane

(1.0g 3.4mmol) adds 4.12ml 1M boron tribromide/methylene dichloride in the stirred solution of the 10ml methylene dichloride of (seeing embodiment 8, the preparation of portion C) to 5-bromo-2-methyl-4 '-methoxyl group ditans of-78 ℃.After 2 hours, keep this reaction 20 hours, the no raw material existence of HPLC indication this moment in-40 ℃.Should react with the aqueous sodium hydroxide solution quencher, use dichloromethane extraction 3 times, use the salt water washing, then through dried over sodium sulfate.After removing volatile matter, obtaining 0.84g is 5-bromo-2-methyl-the 4 '-hydroxy diphenyl methane of soup compound, and it need not to be further purified and uses.

B.5-bromo-2-methyl-4 '-benzyloxy ditan

To contain part A 5-bromo-2-methyl-4 '-hydroxy diphenyl methane (735mg, 2.65mmol), bromotoluene (548mg, 3.2mmol) and salt of wormwood (732mg, 10mlDMF solution stirring 5.3mmol) is spent the night.Then with this reactant in 60 ℃ of heating 6 hours, impel 80% to 100% conversion.Behind the dilute with water, with this reactant of ethyl acetate extraction 3 times.The ethyl acetate layer that water and salt water washing merge is then through dried over sodium sulfate.After the solvent removed in vacuo, residue with 3% ethyl acetate/hexane wash-out, obtains 785mg 5-bromo-2-methyl-4 '-benzyloxy ditan through silica gel column chromatography, is colourless soup compound.

Under argon atmospher, to the 5-of-78 ℃ part B bromo-2-methyl-4 '-benzyloxy ditan (0.43g, 1.2mmol) hexane solution of dropping 0.68ml 1.9M n-Butyl Lithium in the stirred solution of the anhydrous THF of 7ml.After 30 minutes, with being added in 2,3,4 among the 3ml THF in 1 minute, 6-four-O-benzyl-β-maltonic acid lactone (0.7g, 1.3mmol).Stir these solution 0.75 hour in-78 ℃, use the saturated aqueous ammonium chloride quencher then.After being warmed to 20 ℃, this reactant of 2 times of dilutions of water is used ethyl acetate extraction 3 times then.With the ethyl acetate part of salt water washing merging, through dried over sodium sulfate.After concentrating with rotatory evaporator, obtain the required title lactol into the 0.96g of colourless soup compound, it need not to be further purified and is used for subsequently step.

(0.96g 1.16mmol) adds iPr in the stirred solution of 10ml MeCN to the lactol of-30 ℃ portion C ₃(0.37g 2.3mmol), then adds BF to SiH ₃Et ₂O (0.2g, 1.4mmol).In-40 ℃ to-30 ℃ after 3 hours, add the unsaturated carbonate aqueous solutions of potassium, stirred these suspension 1 hour, water and ethyl acetate dilution then in 20 ℃.With the organic layer that derives from 3 parts of ethyl acetate extracts of salt water washing merging, through dried over sodium sulfate.Concentrate with rotatory evaporator, obtain the faint yellow soup compound of 1.2g.Through silica gel column chromatography, with the nonpolar impurity of 9% ethyl acetate/hexane wash-out; 10% ethyl acetate/hexane wash-out obtains required β C-aryl glucoside (0.26g).

Under 1 normal atmosphere hydrogen, (255mg 0.31mmol) is containing 10%Pd (OH) with five-O-benzyl C-glucoside of part D ₂Solution stirring in the ethyl acetate (10ml) of/C (65mg) 24 hours.After HPLC showed that reaction is finished, filtering catalyst except that desolvating, obtained 115mg white glass shape solid with rotatory evaporator, and it need not to be further purified and uses.

(80mg, screw thread test tube 0.16mmol) are cooled to-78 ℃, to wherein adding 1.5g CHClF with C-glucoside that the phenol of magnetic stirring apparatus, 4ml Virahol and part E is housed ₂(forming) by this gas of condensation.After adding the aqueous sodium hydroxide solution of 3ml 25%, with this test tube of Teflon plug seal, and be heated to 70 ℃ 2 hours.Obtain containing raw material phenol through HPLC: the reactant of 2: 3 mixtures of required ether.(attempting to impel the effort of conversion not succeed) by prolonging the reaction times.After the cooling, add the 1N HCl of capacity, making pH is 2, after this removes most of volatile matter with rotatory evaporator.After making residue be dissolved in 2: 1 methanol, through being equipped with YMC S5C-18 reversed-phase column (20 * 100mm) preparation HPLC purifying, with 10 minutes linear gradient liquid of 45%-90% methanol aqueous solution,, obtain the required phenolic ether of 40mg with 20ml/ minute speed wash-out.

The HPLC retention time: 6.6 minutes, 95% purity, YMC S5 C-18 4.6 * 50mm post 2.5ml/ minute, detects in 220nM; 0-100%B gradient liquid 8 minutes kept 5 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(400MHz，CD ₃OD)δ7.22(s，1H)，7.20(m，1H)，7.12(m，1H)，7.06(ABq，4H)，6.73(t，1H，J＝27Hz)，4.09(d，1H，J＝9Hz)，3.98(s，2H)，3.89(d，1H)，3.68(dd，1H)，3.47-3.30(m，4H)，2.17(s，3H)。

¹³C NMR(100MHz，CD ₃OD)δ138.7，138.2，137.7，136.6，130.3，130.2，130.1，126.4，119.3，117.0，82.7，81.4，79.0，75.6，71.1，62.3，49.0，38.8，18.6。

C ₂₁H ₂₄F ₂O ₆LC-MS[M+NH4] analytical calculation value 428; Measured value 428.

Embodiment 10

A.5-bromo-2-methyl-4 '-methylthio group (thiomethyl) benzophenone

(535mg, (466mg, 2mmol) (270mg is in the solution of the stirring of 5ml dithiocarbonic anhydride 2.3mmol) for (it prepares referring to embodiment 8 part B) and thioanisole 4mmol) to join 4 ℃ crude product 5-bromo-2-methyl benzoyl chloride with aluminum chloride.After being warmed to 20 ℃ with 1 hour, this reactant was stirred 2 hours, use 1N HCl quencher then.Subsequently, dilute this suspension, be stirred to all solids and be dissolved in the solution with 50ml water.With this mixture of ethyl acetate extraction 3 times.The organic extraction that merges with each washing of 1N HCl, water, sodium bicarbonate aqueous solution and salt solution 1 time is then through dried over sodium sulfate.After removing volatile matter, residue obtains 450mg 5-bromo-2-methyl-4 '-methylthio group benzophenone through silica gel column chromatography with 15% ethyl acetate/hexane wash-out, is white solid.

B.5-bromo-2-methyl-4 '-methylthio group ditan

With Et ₃SiH (0.45ml, 2.85mmol), BF ₃Et ₂O (0.3ml, 2.4mmol) and 5-bromo-2-methyl-the 4 '-methylthio group benzophenone of part A (450mg, 1.4mmol) solution in 1: 9 mixture of 3ml methylene dichloride/MeCN spends the night in 20 ℃ of stirrings.Behind 10% sodium hydroxide quencher and dilute with water, with this reactant of ethyl acetate extraction 3 times.Wash the organic layer 2 times of merging with water, with salt water washing 1 time, then through dried over sodium sulfate.After removing volatile matter, residue with 5% ethyl acetate/hexane wash-out, obtains 416mg 5-bromo-2-methyl-4 '-methylthio group ditan through silica gel column chromatography, is colorless oil.

Under argon atmospher, to the 5-of-78 ℃ part B bromo-2-methyl-4 '-methylthio group ditan (200mg, 0.65mmol) hexane solution of dropping 0.42ml 1.8M n-Butyl Lithium in the stirred solution of the anhydrous THF of 10ml.After 2 hours, by conduit with this solution be transferred in 5ml THF 2,3,4, (0.88g is in-78 ℃ stirred solution 1.6mmol) for 6-four-O-benzyl-β-maltonic acid lactone.Stir these solution 2 hours in-78 ℃, use the saturated aqueous ammonium chloride quencher then.After being warmed to 20 ℃, this reactant of 2 times of dilutions of water is used ethyl acetate extraction 3 times then.With the ethyl acetate part of salt water washing merging, through dried over sodium sulfate.After concentrating with rotatory evaporator, obtaining 550mg is the required title lactol of colourless soup compound, and it need not to be further purified and is used for subsequently step.

(550mg 0.72mmol) adds iPr in the stirred solution of 6ml MeCN to the lactol of-40 ℃ portion C ₃(0.22ml 1.0mmol), then adds BF to SiH ₃Et ₂O (0.11ml, 0.8mmol).In-40 ℃ to-30 ℃ after 1.5 hours, when tlc shows that reaction is finished, add the unsaturated carbonate aqueous solutions of potassium, stirred these suspension 1 hour, water and ethyl acetate dilution then in 20 ℃.With the organic layer that derives from 3 parts of ethyl acetate extracts of salt water washing merging, through dried over sodium sulfate.Concentrate with rotatory evaporator.Residue is through silica gel column chromatography, and as eluent, wash-out obtains the required β C-aryl glucoside of 240mg with 9% ethyl acetate/hexane.

(70mg 0.1mmol) is containing BF with four-O-benzyl C-glucoside of part D ₃Et ₂(0.24ml, the solution among EtSH 2mmol) (1.5ml) stirred 2 hours in 20 ℃ O.Adding other 0.12ml BF ₃Et ₂Behind the O 1 hour subsequently, reaction is finished.Should react by the quencher of slow adding 0.4ml pyridine, dilute with aqueous ammonium chloride solution then.With the organic layer that derives from 3 parts of ethyl acetate extracts of salt water washing merging, through dried over sodium sulfate.Concentrate with rotatory evaporator.Use the C-18 reversed-phase column,, obtain the white lyophilized products of the required β C-glucoside of 20mg after the freeze-drying through preparation property HPLC purifying residue.

The HPLC retention time: 3.8 minutes, 95% purity, YMC S5 C-18 4.6 * 50mm post 2.5ml/ minute, detects in 220nM; 0-100%B gradient liquid 4 minutes kept 4 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(500MHz，CD ₃OD)δ7.21-7.11(m，5H)，7.05(d，2H，J＝8.0Hz)，4.08(d，1H，J＝9.1Hz)，3.98(s，2H)，3.87(d，1H，J＝12.6Hz)，3.68(dd，1H，J＝5.2，12.1Hz)，3.49-3.30(m，4H)，2.41(s，3H)。

¹³C NMR(125MHz，CD ₃OD)δ139.8，138.9，138.4，137.5，137.1，131.1，130.9，129.1，130.3，127.8，127.1，83.6，82.2，79.8，76.4，72.0，63.2，39.9，19.5，16.1。

C ₂₁H ₂₆O ₅S LC-MS[M+NH ₄] analytical calculation value 408; Measured value 408.

Embodiment 11

A.5-bromo-2-chloro-4 '-methylthio group benzophenone

(506mg 2.12mmol) adds 2 DMF in the stirred suspension in the 10ml methylene dichloride that contains oxalyl chloride (2.4mmol) to 5-bromo-2-chlorinated benzene formic acid.As soon as the violent release of gas stops, stirring this reactant 1.5 hours, remove volatile matter with rotatory evaporator then.After crude product 5-bromo-2-chlorinated benzene formyl chloride is dissolved in the 8ml dithiocarbonic anhydride, stirred mixture is cooled to 4 ℃, add then thioanisole (260mg, 2.12mmol), then add aluminum chloride (566mg, 4.25mmol).Be warmed to 20 ℃ after 1 hour, this reactant was stirred 20 hours, use 1N HCl quencher then.Subsequently, dilute this suspension, be stirred to all solids and be dissolved in the solution with 50ml water.With this mixture of ethyl acetate extraction 3 times.The organic extraction that merges with each washing of 1N HCl, water, sodium bicarbonate aqueous solution and salt solution 1 time is through dried over sodium sulfate.After removing volatile matter, 710mg crude product 5-bromo-2-chloro-4 '-methylthio group benzophenone need not to be further purified.

B.5-bromo-2-chloro-4 '-methylthio group ditan

With Et ₃SiH (1.4ml, 8.8mmol), BF ₃Et ₂O (0.83ml, 6.6mmol) and 5-bromo-2-chloro-4 '-methylthio group benzophenone of part A (710mg, 2.1mmol) solution in 1: 4 mixture of 10ml methylene dichloride/MeCN stirred 2 hours in 20 ℃.Behind 10% sodium bicarbonate quencher and dilute with water, with this reactant of ethyl acetate extraction 3 times.Wash the organic layer 2 times of merging with water, with salt water washing 1 time, then through dried over sodium sulfate.After removing volatile matter, residue with 5% ethyl acetate/hexane wash-out, obtains 630mg 5-bromo-2-chloro-4 '-methylthio group ditan through silica gel column chromatography, is colorless oil.

Under argon atmospher, to the 5-of-78 ℃ part B bromo-2-chloro-4 '-methylthio group ditan (200mg, 0.61mmol) hexane solution of dropping 0.48ml 1.5M n-Butyl Lithium in the stirred solution of the anhydrous THF of 6ml.After 35 minutes, by conduit with this solution be transferred in 5ml THF 2,3,4, (361mg is in-78 ℃ stirred solution 0.67mmol) for 6-four-O-benzyl-β-maltonic acid lactone.Stir these solution 1.5 hours in-78 ℃, use the saturated aqueous ammonium chloride quencher then.After being warmed to 20 ℃, this reactant of 2 times of dilutions of water is used ethyl acetate extraction 3 times then.With the ethyl acetate part of salt water washing merging, through dried over sodium sulfate.After concentrating with rotatory evaporator, residue obtains the required title lactol of 250mg through silica gel column chromatography with 20% ethyl acetate/hexane wash-out.

(250mg 0.32mmol) adds iPr in the stirred solution of 5ml MeCN to the lactol of-30 ℃ portion C ₃(0.10ml 0.56mmol), then adds BF to SiH ₃Et ₂O (0.048ml, 0.38mmol).In-30 ℃ after 0.5 hour, when tlc shows that reaction is finished, add saturated sodium bicarbonate aqueous solution, stirred these suspension 1 hour, water and ethyl acetate dilution then in 20 ℃.With the organic layer that derives from 3 parts of ethyl acetate extracts of salt water washing merging, through dried over sodium sulfate.Concentrate with rotatory evaporator.Residue is through silica gel column chromatography, and as eluent, wash-out obtains the required β C-aryl glucoside of 200mg with 9% ethyl acetate/hexane.

(60mg 0.1mmol) is containing BF with four-O-benzyl C-glucoside of part D ₃Et ₂(0.24ml, the solution among EtSH 2mmol) (2ml) stirred 3 hours in 20 ℃ O.Should react by the quencher of slow adding 0.4ml pyridine, dilute with aqueous ammonium chloride solution then.The organic layer that derives from 3 parts of ethyl acetate extracts with the salt water washing merges through dried over sodium sulfate, concentrates with rotatory evaporator.Use the C-18 reversed-phase column,, obtain the white lyophilized products of the required β C-glucoside of 21.5mg after the freeze-drying through preparation property HPLC purifying residue.

The HPLC retention time: 3.96 minutes, 95% purity, YMC S5 C-18 4.6 * 50mm post 2.5ml/ minute, detects in 220nm; 0-100%B gradient liquid 4 minutes kept 4 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(400MHz，CD ₃OD)δ7.36-7.27(m，3H)，7.15(d，2H，J＝8.3Hz)，7.11(d，2H，J＝8.3Hz)，4.10-4.04(m，3H)，3.87(d，1H，J＝12Hz)，3.70(dd，1H，J＝7.1，11.8Hz)，3.47-3.26(m，4H)，2.42(s，3H)。

¹³C NMR(100MHz，CD ₃OD)δ140.1，139.3，138.0，137.5，134.5，132.0，130.4，130.2，128.4，128.0，82.9，82.8，82.2，79.7，76.5，71.8，63.1，39.5，16.1。

C ₂₀H ₂₃ClO ₅S LC-MS[M-H] analytical calculation value 409; Measured value 409.

Embodiment 12

A.5-bromo-2-chloro-4 '-methoxyl group benzophenone

(506mg 2.12mmol) adds 2 DMF to the 5-bromo-2-chlorinated benzene formic acid that obtains to purchase in 10ml contains stirred suspension in the methylene dichloride of oxalyl chloride (2.4mmol).As soon as the violent release of gas stops, stirring this reactant 1.5 hours, remove volatile matter with rotatory evaporator then.After crude product 5-bromo-2-chlorinated benzene formyl chloride is dissolved in the 8ml dithiocarbonic anhydride, stirred mixture is cooled to 4 ℃, add then methyl-phenoxide (240mg, 2.12mmol), then add aluminum chloride (566mg, 4.25mmol).Be warmed to 20 ℃ after 1 hour, this reactant was stirred 20 hours, use 1N HCl quencher then.Subsequently, dilute this suspension, be stirred to all solids and be dissolved in the solution with 50ml water.With this mixture of ethyl acetate extraction 3 times.The organic layer that merges with each washing of 1N HCl, water, sodium bicarbonate aqueous solution and salt solution 1 time is then through dried over sodium sulfate.After removing volatile matter, residue obtains 450mg 5-bromo-2-chloro-4 '-methoxyl group benzophenone through silica gel column chromatography with 15% ethyl acetate/hexane wash-out.

B.5-bromo-2-chloro-4 '-methoxyl group ditan

With Et ₃SiH (0.45ml, 2.85mmol), BF ₃Et ₂(0.3ml, 2.4mmol) (450mg, 1.4mmol) solution in 1: 9 mixture of 3ml methylene dichloride/MeCN spends the night in 20 ℃ of stirrings O with 5-bromo-2-chloro-4 '-methoxyl group benzophenone.Behind 10% sodium hydroxide quencher and dilute with water, with this reactant of ethyl acetate extraction 3 times.Wash the organic layer 2 times of merging with water, with salt water washing 1 time, then through dried over sodium sulfate.After removing volatile matter, residue obtains 416mg 5-bromo-2-chloro-4 '-methoxyl group ditan through silica gel column chromatography with 2% ethyl acetate/hexane wash-out, is colorless oil.

Under argon atmospher, to the 5-of-78 ℃ part B bromo-2-chloro-4 '-methoxyl group ditan (212mg, 0.68mmol) hexane solution of dropping 0.36ml 1.9M n-Butyl Lithium in the stirred solution of the anhydrous THF of 8ml.After 30 minutes, by conduit with this solution be transferred in 5ml THF 2,3,4,6-four-O-benzyl-β-maltonic acid lactone (0.39g, hold in the liquid by 0.71mmol)-78 ℃ stirring.Stir these solution 2 hours in-78 ℃, use the saturated aqueous ammonium chloride quencher then.After being warmed to 20 ℃, this reactant of 2 times of dilutions of water is used ethyl acetate extraction 3 times then.With the ethyl acetate part of salt water washing merging, through dried over sodium sulfate.After concentrating with rotatory evaporator, residue obtains the required title lactol of 142mg through silica gel column chromatography with 20% ethyl acetate/hexane wash-out.

(142mg 0.18mmol) adds iPr in the stirred solution of 1.5ml MeCN to the lactol of-40 ℃ portion C ₃(0.041ml 0.2mmol), then adds BF to SiH ₃Et ₂O (0.026ml, 0.2mmol).In-40 ℃ after 2 hours, when showing reaction, finishes tlc, add saturated sodium bicarbonate aqueous solution, water and methylene dichloride dilution.The organic layer that derives from 3 parts of dichloromethane extracts with the salt water washing merges through dried over sodium sulfate, concentrates with rotatory evaporator.Residue is through silica gel column chromatography, and as eluent, wash-out obtains the required β C-aryl glucoside of 139mg with 25% ethyl acetate/hexane.

(136mg 0.18mmol) is containing BF with four-O-benzyl C-glucoside of part D ₃Et ₂(0.46ml, the solution among EtSH 3.6mmol) (1.0ml) stirred 4 hours in 20 ℃ O.Dilute this reactant with methylene dichloride, concentrate with rotatory evaporator then.After residue is dissolved in the methylene dichloride,,, concentrate with rotatory evaporator through dried over sodium sulfate with aqueous ammonium chloride solution, water, salt water washing.Use the C-18 reversed-phase column,, obtain the required β C-glucoside of 26mg after the freeze-drying, be white lyophilized products through preparation property HPLC purifying crude product.

The HPLC retention time: 3.07 minutes, 95% purity, YMC S5 C-18 4.6 * 50mm post 2.5ml/ minute, detects in 220nM; 0-100%B gradient liquid 4 minutes kept 4 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(500MHz，CD ₃OD)δ7.35-7.28(m，3H)，7.1(d，2H，J＝8.8Hz)，6.8(d，2H，J＝8.3Hz)，4.05-3.90(m，3H)，3.80(d，1H，J＝12.3Hz)，3.67(s，3H)，3.61(dd，1H，J＝4.8，11.9Hz)，)，3.42-3.25(m，4H)Hz)。

¹³C NMR(125MHz，CD ₃OD)δ159.6，140.0，139.9，134.5，133.0，131.9，130.8，130.1，114.8，82.9，82.2，79.8，76.5，71.9，63.1，55.6，39.2。

C ₂₀H ₂₃ClO ₆LC-MS[M+NH ₄] analytical calculation value 412; Measured value 412.

Embodiment 13

A.5-bromo-2-methoxyl group-4 '-ethyl diphenyl-carbinol

Under argon atmospher, with 10 fens clockwise right-(2.03g 11mmol) is added in 5ml 2.5M n-Butyl Lithium (12mmol) in the hexane to bromo ethyl phenenyl in-78 ℃ the stirred solution in the anhydrous THF of 10ml.Make temperature rise to-10 ℃ 2 hours, (2.15g 10mmol) before, is cooled to-78 ℃ with this reactant adding solid 5-bromo-2-methoxybenzaldehyde.After 20 ℃ of stirrings are spent the night, should react with the saturated aqueous ammonium chloride quencher, 5 times of dilute with waters are used ethyl acetate extraction 3 times then.With the ethyl acetate part of salt water washing merging, through dried over sodium sulfate.After using rotatory evaporator to concentrate, residue obtains 1.44g 5-bromo-2-methoxyl group-4 '-ethyl diphenyl-carbinol through silica gel column chromatography with 10% ethyl acetate/hexane wash-out.

B.5-bromo-2-methoxyl group-4 '-ethyl ditan

To contain part A crude product 5-bromo-2-methoxyl group-4 '-ethyl diphenyl-carbinol (1.44g, 4.5mmol), Et ₃SiH (0.75ml, 5mmol) and BF ₃Et ₂(0.6ml, 1: 8 the solution of 9ml methylene dichloride/MeCN 6.4mmol) spends the night in 20 ℃ of stirrings O.After saturated aqueous sodium hydroxide solution quencher, with this mixture of ethyl acetate extraction 3 times.With the ethyl acetate part of salt water washing merging, through dried over sodium sulfate.After using rotatory evaporator to concentrate, residue obtains 1.28g 5-bromo-2-methoxyl group-4 '-ethyl ditan through silica gel column chromatography with 2% ethyl acetate/hexane wash-out.

Under argon atmospher, to the 5-of-78 ℃ part B bromo-2-methoxyl group-4 '-ethyl ditan (0.25g, 0.82mmol) hexane solution of dropping 0.5ml 1.8M n-Butyl Lithium in the stirred solution of the anhydrous THF of 7ml.After 2 hours, with being added in 2,3,4 among the 3ml THF in 1 minute, 6-four-O-benzyl-β-maltonic acid lactone (0.48g, 0.9mmol).Stir these solution 2 hours in-78 ℃, use the saturated aqueous ammonium chloride quencher then.After being warmed to 20 ℃, this reactant of 5 times of dilutions of water is used ethyl acetate extraction 3 times then.With the ethyl acetate part of salt water washing merging, through dried over sodium sulfate.After concentrating with rotatory evaporator, obtain the required title lactol into the 0.67g of faint yellow soup compound, it need not to be further purified and is used for subsequently step.

(450mg 0.59mmol) adds iPr in the stirred solution of 10ml MeCN to the lactol of-30 ℃ portion C ₃(0.2ml 0.9mmol), then adds BF to SiH ₃Et ₂O (0.1ml, 0.7mmol).In-40 ℃ after 1.5 hours, tlc shows that reaction finishes, and adds the sodium bicarbonate aqueous solution quencher, uses ethyl acetate extraction subsequently 3 times.Organic layer with the salt water washing merges through dried over sodium sulfate, concentrates with rotatory evaporator.Residue obtains the required β C-aryl glucoside of 320mg through silica gel column chromatography with 10% ethyl acetate/hexane wash-out.

Under 1 normal atmosphere hydrogen, (320mg 0.7mmol) is containing 10%Pd (OH) with four-O-benzyl C-glucoside of part D ₂Solution stirring in the ethyl acetate (15ml) of/C (30mg) is spent the night.After HPLC showed that reaction is finished, filtering catalyst removed with rotatory evaporator and to desolvate.Use the C-18 reversed-phase column, HPLC is further purified crude product through preparation property, obtains the required β C-glucoside of 24mg after the freeze-drying, is white solid.

The HPLC retention time: 3.84 minutes, 95% purity, YMC S5 C-18 4.6 * 50mm post 2.5ml/ minute, detects in 220nM; 0-100%B gradient liquid 4 minutes kept 4 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(500MHz，CD ₃OD)δ7.23(d，1H，J＝7Hz)，7.17(s，1H)，7.05(ABq，4H)，6.89(d，1H，J＝7Hz)，4.02(d，1H，J＝9Hz)，3.92-3.83(m，3H)，3.76(s，3H)，3.66(dd，1H)，3.45-3.29(m，4H)，2.55(q，2H)，1.16(t，3H)。

C ₂₂H ₂₈O ₆LC-MS[M+NH ₄] analytical calculation value 406; Measured value 406.

Embodiment 14

A.N-ethyl-N-4-methoxy-benzyl-2, the 6-dihydroxy benzoyl amine

To N-ethyl-4-methoxybenzylamine (1.07g adds 2 in the stirred solution of DMF 6.49mmol) (10ml), the 6-resorcylic acid (1.0g, 6.49mmol), then add HOAt (0.97g, 7.14mmol) and EDC (1.31g, 6.81mmol).After stirring is spent the night, dilute this reactant, wash with water then 3 times with ethyl acetate.The water layer that merges with ethyl acetate extraction 1 time.Merge organic moiety,,, concentrate with rotatory evaporator then through dried over sodium sulfate with salt water washing 1 time.Residue is through silica gel column chromatography, with 75% ethyl acetate/hexane as eluent.Be further purified the valuable impure part that obtains by silica gel column chromatography.Obtain required N-ethyl-N-4-methoxy-benzyl-2 of 631mg altogether, the 6-dihydroxy benzoyl amine.

Adopt Dean Stark trap, with the acid amides of part A (630mg, 2.09mmol), CdCO ₃(939mg, 5.44mmol) stirred suspension in toluene (30ml) refluxed 1.5 hours, added 2,3,4 then, 6-four-O-ethanoyl-α-D-glucopyranosyl (glucosopyranosyl) bromine (1.12g, 2.72mmol).Reflux after 15 hours, analyzing through tlc does not have the raw material acid amides to exist.By the suspension of diatomite filtration heat, wash it with hot PhMe, then with hot chloroform washing 3 times.After removing volatile matter with rotatory evaporator, residue is through silica gel column chromatography.With the mixture of 1: 1 ethyl acetate/hexane wash-out O-glucoside, obtain the tetraacetate of required title C-glucoside then, obtain the required title C-glucoside that 172mg contains a large amount of impurity.

The impurity ester of part B is being contained potassium hydroxide (140mg, the middle stirring of 6: 1 ethanol/waters (1.4ml) 2.5mmol) 16 hours.Make the solution of generation be cooled to 4 ℃, be acidified to pH 5, use ethyl acetate extraction then 2 times.Ethyl acetate layer with the salt water washing merges through dried over sodium sulfate, concentrates with rotatory evaporator then.With C-18 YMC reversed-phase column, through preparation property HPLC purifying resistates, used 45-90% methanol gradient liquid 30 minutes, wash-out obtains required title C-glucoside (7.8mg).

HPLC:99.1%; Shimadzu LC-6A, YMC S3 ODS (6.0 * 150mm); Flow velocity 1.5ml/ minute; Detect in 220nM; 30 minutes wash-outs (A=90% water, 10% methyl alcohol, 0.2% phosphoric acid, and B=90% methyl alcohol, 10% water, 0.2% phosphoric acid) of 0-100%B gradient liquid; Retention time=23.4 minute.

¹H NMR(400MHz，CD ₃OD)δ1.22(3H，t，J＝7.2Hz)，3.4-3.5(6H，m)，3.73(3H，s)，3.74(1H，m)，3.77(1H，m)，3.8-3.9(2H，m)，4.36(1H，d，J＝9.3Hz)，6.77(2H，d，J＝8.6Hz)，7.11(2H，d，J＝8.6Hz)，7.18(1H，s)。

¹³C NMR(125MHz，CD ₃OD)δ14.9，35.1，35.1，55.7，62.5，71.2，75.8，79.6，80.3，82.3，104.8，114.7，117.1，122.7，130.7，134.5，134.6，151，159.3，161，171.9

C ₂₃H ₂₉NO ₉LC-MS[M-H] analytical calculation value 462; Measured value 462.

Embodiment 15

Under 80 ℃, argon atmospher, with the β of embodiment 3 part B--bromo phenyl-C-glucoside (100mg, 0.14mmol), right-methylphenylboronic acid (59mg, 0.43mmol), yellow soda ash (46mg, 0.43mmol) and four (triphenyl phosphines) close palladium, and (153mg, 0.13mmol) mixture in 3: 1 PhMe/EtOH stirred 15 hours.After removing volatile matter with rotatory evaporator, residue with 10: 1 required title xenyl C-glucosides (90mg) of hexane/ethyl acetate wash-out, is clarification oily matter through silica gel column chromatography.

Under argon atmospher, (65mg is added in the 0.37ml 1MBCl in the methylene dichloride in the methylene dichloride of stirring 0.09mmol) (0.4ml) solution to four-O-of-78 ℃ part A benzylic ether ₃After 1 hour, should react, and make to be warmed to 20 ℃ with the quencher of 2ml methyl alcohol.With sodium bicarbonate aqueous solution with pH regulator after about 7, with this suspension of dichloromethane extraction 2 times.The organic layer that merges through dried over mgso also concentrates.Use the C-18 reversed-phase column, behind the residue that preparation property HPLC purifying obtains, obtain the final title product of 6.6mg.(note: this product of strongly-acid medium partial destruction that is produced behind the methyl alcohol quencher boron trichloride).

The HPLC retention time: 6.353 minutes, 100% purity, Zorbax C-18 4.6 * 50mm post 2.5ml/ minute, detects in 220nM; 0-100%B gradient liquid 8 minutes kept 5 minutes in 100%B.Solvent orange 2 A: 10% methanol+0.2% phosphoric acid.Solvent B:90% methanol+0.2% phosphoric acid.

¹H NMR(400MHz，CD ₃OD)δ7.65(s，1H)，7.53-7.50(m，3H)，7.39-3.37(m，2H)，7.23(d，2H，J＝7.9Hz)，4.20(d，1H，J＝9.3Hz)，3.89(dd，1H，J＝2.2，11.9Hz)，3.71(dd，1H，J＝5.7，11.9Hz)，3.50-3.40(m，4H)，2.36(s，3H)

C ₁₉H ₂₂O ₅The low MS[M-H that differentiates] analytical calculation value 329; Measured value 329.

Embodiment 16-80

Adopt the method for above embodiment 1-15 and reaction process 1-9 to prepare the compound of listing in the embodiment 16-80 in following table 1 and 2.Should be appreciated that A can be (CH to adopt the method for above embodiment 1-15 and reaction process 1-9 can prepare wherein ₂) _n, any one and R among O, NH or the S ¹, R ², R ^2a, R ³And R ⁴Can be any as defined above substituent compound, A can be connected in ortho position, a position or the contraposition of the aromatic ring that is connected in glucoside.

Table 1

Embodiment	A	R 3	The method of embodiment #	LC/MS or MS (M+H) +
					16	CH 2	4-Me	1	345
17	CH 2	4-OH	1	347
					18	CH 2	3-Me	2	345
19	CH 2	H	3	331
					20	CH 2	3-OMe	3	361
21	CH 2	4-CO 2Me	3	389
					22	CH 2	3，4-(OCH 2O)	3	375
23	CH 2	4-CF 3	3	399
					24	CH 2	4-NHAc	3	388
25	CH 2	4-SO 2Me	3	409
					26	CH 2	4-Ph	3	407
27	CH 2	4-NHSO 2Ph-4′-Me	3	500
					28	CH 2	4-NHSO 2Me	3	424
29	CH 2	4-CO 2H	3	375
					30	CH 2	The 4-thiadiazoles	3	415
31	CH 2	The 4-tetrazolium	3	399
					32	CH 2	4-OCH 2Ph-4′-CN	1	462
33	CH 2	4-OCHF 2	1	397
					34	CH 2	4-iPr	3	373

35	CH 2	2-iPr	3	373
					36	CH 2	4-O-nPr	1	389
37	CH 2	4-tetrazolium-2 '-Me	3	413
					38	CH 2	4-four-1 '-Me	3	413
39	CH 2	4-OPh	1	423
					40	CH 2	4-nPr	1	373
41	CH 2	4-nBu	1	387
					42	CH 2	4-SO 2Et	1	423
43	CH 2	4-SO 2-nPr	1	437
					44	CH 2	4-SO 2Ph	3	471
45	CH 2	4-SOMe	4	393
					46	Key	H	15	317
47	Key	3-Me	15	331
					48	Key	4-MeO	15	347
49	(CH 2) 2	H	1	343(M-H)
					50	(CH 2) 2	4-Me	1	357(M-H)
51	(CH 2) 3	H	1	376(M+NH4)
					52	(CH 2) 3	4-Me	1	390(M+NH4)
53	(CH 2) 3	3-Me	1	390(M+NH4)
					54	Key (contraposition connection)	H	15	317
55	CH 2(ortho position connection)	H	1	331
					56	CH 2(ortho position connection)	4-Et	1	376(M+NH4)

57	O	4-Me	Flow process 8	364(M+NH4)
					58	S	4-Me	Flow process 9	380(M+NH4)

Table 2

Embodiment	A	R 1	R 2	R 3	The method of embodiment #	LC/MS or MS (M+H) +
59	CH 2	2-Me	H	4-Et	1	371(M-H)
							60	CH 2	4-Me	H	4-Et	8	371(M-H)
61	CH 2	4-Me	H	4-SO 2Me	8	445(M+Na)
							62	CH 2	4-Me	H	4-OH	9	359(M-H)
63	CH 2	4-Me	H	4-S(O)Me	10	407(M+H)
							64	CH 2	4-Me	H	4-F	8	385(M+NH4)
65	CH 2	4-Me	H	4-Cl	8	377(M-H)
							66	CH 2	4-Me	H	4-Me	8	357(M-H)
67	CH 2	4-Me	H	H	8	343(M-H)
							68	CH 2	4-Me	6-Me	4-OMe	1	406(M+NH4)
69	CH 2	4-F	H	4-OMe	1	396(M+NH4)
							70	CH 2	4-Cl	H	4-SOMe	11	427(M+H)
71	CH 2	4-Cl	H	4-SO 2Me	11	441(M-H)
							72	CH 2	4-Cl	H	4-OCHF 2	9	448(M+NH4)

73	CH 2	4-Et	H	4-OMe	8	406(M+NH4)
							74	CH 2	4-iPr	H	4-OMe	8	420(M+NH4)
75	CH 2	4-iPr	H	4-SMe	10	417(M-H)
							76	CH 2	4-iPr	H	4-SO 2Me	10	439(M-H)
77	CH 2	4，5-OCH 2O	H	4-Et	1	403(M+H)
							78	CH 2	5-Me	H	4-Et	1	390(M+NH4)
79	CH 2	5-Me	6-Me	4-OMe	1	406(M+NH4)
							80	CH 2	6-Me	H	4-Et	8	395(M+Na)

Claims (25)

1. drug regimen, it comprises the antidiabetic medicine of sodium dependent glucose transporter inhibitors compound and non-sodium dependent glucose transporter inhibitors, medicine, anti-obesity medicine, antihypertensive drug, antiplatelet drug, Antiatherosclerosis medicine and/or the hypolipidemic of treatment diabetic complication;

Wherein said sodium dependent glucose transporter inhibitors compound is to have the compound of following structure or salt or the steric isomer that it is pharmaceutically accepted:

Wherein

R ¹, R ²And R ^2aIndependent is hydrogen, OH, OR ⁵, C ₁-C ₁₀Alkyl or halogen;

R ³And R ⁴Independent is hydrogen, OH, OR ^5a, O aryl, OCH ₂Aryl, C ₁-C ₁₀Alkyl, CF ₃,-OCHF ₂,-OCF ₃, halogen ,-CO ₂R ^5b,-CO ₂H, COR ^6b,-CH (OH) R ^6c,-NHCOR ^5c,-NHSO ₂R ^5d,-NHSO ₂Aryl, aryl ,-SR ^5e,-SOR ^5f,-SO ₂R ^5gOr-SO ₂Aryl;

R ⁵, R ^5a, R ^5b, R ^5c, R ^5d, R ^5e, R ^5fAnd R ^5gIndependent is C ₁-C ₁₀Alkyl;

R ^6bAnd R ^6cIndependent is C ₁-C ₁₀Alkyl;

A is O, S or (CH ₂) _n, wherein n is 1-3;

Condition be when A be (CH ₂) _n, wherein n be 1,2 or 3 or A be O, and R ¹, R ²And R ^2aIn at least one be OH or OR ⁵The time, R then ³And R ⁴In at least one be CF ₃,-OCHF ₂,-OCF ₃,-CO ₂R ^5b,-CH (OH) R ^6c, COR ^6b,-NHCOR ^5c,-NHSO ₂R ^5d,-NHSO ₂Aryl, aryl ,-SR ^5e,-SOR ^5f,-SO ₂R ^5gOr-SO ₂Aryl.

2. the drug regimen of claim 1, condition be when A be (CH ₂) _n, wherein n be 1,2 or 3 or A be O, and R ¹, R ², R ^2a, R ³And R ⁴In at least one be OH or OR ⁵The time, R then ³And R ⁴In at least one be CF ₃,-OCHF ₂,-OCF ₃,-CO ₂R ^5b,-NHCOR ^5c,-NHSO ₂R ^5d,-NHSO ₂Aryl, aryl ,-SR ^5e, SOR ^5f,-SO ₂R ^5g,-SO ₂Aryl or halogen; R wherein ⁵, R ^5b, R ^5c, R ^5d, R ^5e, R ^5fAnd R ^5gIndependent is C ₁-C ₁₀Alkyl.

3. the drug regimen of claim 1, wherein said sodium dependent glucose transporter inhibitors compound has following structure

R wherein ¹-R ⁴, R ^2aWith A as defined in claim 1.

4. the drug regimen of claim 3, wherein A is CH ₂Or O or S.

5. the drug regimen of claim 3, wherein said sodium dependent glucose transporter inhibitors compound has following structure

6. the drug regimen of claim 1, wherein A is (CH ₂) _n, n as defined in claim 1.

7. the drug regimen of claim 1, wherein A is CH ₂Or O or S;

R ¹, R ²And R ^2aIndependently be selected from H, C ₁-C ₈Alkyl, halogen or OR ⁵, perhaps R ¹, R ²And R ^2aIn two be H, and another is C ₁-C ₈Alkyl, halogen or OR ⁵

R ³And R ⁴Independently be selected from C ₁-C ₈Alkyl, OR ^5a,-OCHF ₂,-SR ^5e, OH, CO ₂R ^5b,-COR ^6b,-CH (OH) R ^6c, CF ₃,-NHCOR ^5c,-SOR ^5f,-SO ₂R ^5g, aryl ,-NHSO ₂Aryl ,-NHSO ₂R ^5d, CO ₂H, OCH ₂Aryl ,-OCF ₃, O aryl or H;

R wherein ⁵, R ^5a, R ^5b, R ^5c, R ^5d, R ^5e, R ^5f, R ^5g, R ^6bAnd R ^6cAs defined in claim 1.

8. the drug regimen of claim 7, wherein A is CH ₂R ¹Be hydrogen, halogen or C ₁-C ₈Alkyl; R ²And R ^2aRespectively be H; R ³Be H; R ⁴Be C ₁-C ₈Alkyl-COR ^6b,-CH (OH) R ^6c, OR ^5a,-OCHF ₂,-OCF ₃Or-SR ^5e

R wherein ^5a, R ^5e, R ^6bAnd R ^6cAs defined in claim 1.

9. the drug regimen of claim 8, wherein A is CH ₂R ¹Be hydrogen, halogen or C ₁-C ₈Alkyl; R ⁴Be C ₁-C ₈Alkyl, OR ^5a,-OCHF ₂Or-SR ^5e, R wherein ^5aAnd R ^5eAs defined in claim 1.

10. the drug regimen of claim 8, wherein R ⁴Be 4-C ₂H ₅

11. the drug regimen of claim 1, wherein said sodium dependent glucose transporter inhibitors compound has following structure:

Wherein

(1) A is (CH ₂) ₂, R ³Be H;

(2) A is (CH ₂) ₂, R ³Be 4-Me;

(3) A is (CH ₂) ₃, R ³Be H;

(4) A is (CH ₂) ₃, R ³Be 4-Me; ,

(5) A is (CH ₂) ₃, R ³Be 3-Me;

(6) A is CH ₂, R ³Be H;

(7) A is CH ₂, R ³Be 4-Et;

(8) A is O, R ³Be 4-Me; Or

(9) A is S, R ³Be 4-Me.

12. the drug regimen of claim 1, wherein said sodium dependent glucose transporter inhibitors compound has following structure:

Wherein

(1) A is CH ₂, R ¹Be 2-Me, R ²Be H, R ³Be 4-Et;

(2) A is CH ₂, R ¹Be 4-Me, R ²Be H, R ³Be 4-Et;

(3) A is CH ₂, R ¹Be 4-Me, R ²Be H, R ³Be 4-SO ₂Me;

(4) A is CH ₂, R ¹Be 4-Me, R ²Be H, R ³Be 4-OH;

(5) A is CH ₂, R ¹Be 4-Me, R ²Be H, R ³Be 4-S (O) Me;

(6) A is CH ₂, R ¹Be 4-Me, R ²Be H, R ³Be 4-F;

(7) A is CH ₂, R ¹Be 4-Me, R ²Be H, R ³Be 4-Cl;

(8) A is CH ₂, R ¹Be 4-Me, R ²Be H, R ³Be 4-Me;

(9) A is CH ₂, R ¹Be 4-Me, R ²Be H, R ³Be H;

(10) A is CH ₂, R ¹Be 4-Me, R ²Be 6-Me, R ³Be 4-OMe;

(11) A is CH ₂, R ¹Be 4-F, R ²Be H, R ³Be 4-OMe;

(12) A is CH ₂, R ¹Be 4-Cl, R ²Be H, R ³Be 4-SOMe;

(13) A is CH ₂, R ¹Be 4-Cl, R ²Be H, R ³Be 4-SO ₂Me;

(14) A is CH ₂, R ¹Be 4-Cl, R ²Be H, R ³Be 4-OCHF ₂

(15) A is CH ₂, R ¹Be 4-Et, R ²Be H, R ³Be 4-OMe;

(16) A is CH ₂, R ¹Be 4-iPr, R ²Be H, R ³Be 4-OMe;

(17) A is CH ₂, R ¹Be 4-iPr, R ²Be H, R ³Be 4-SMe;

(18) A is CH ₂, R ¹Be 4-iPr, R ²Be H, R ³Be 4-SO ₂Me;

(19) A is CH ₂, R ¹Be 5-Me, R ²Be H, R ³Be 4-Et;

(20) A is CH ₂, R ¹Be 5-Me, R ²Be 6-Me, R ³Be 4-OMe; Or

(21) A is CH ₂, R ¹Be 6-Me, R ²Be H, R ³Be 4-Et.

13. the drug regimen of claim 1, wherein said sodium dependent glucose transporter inhibitors compound has following structure:

Wherein, R ¹And R ⁴As defined in claim 1.

14. drug regimen, it comprises the antidiabetic medicine of sodium dependent glucose transporter inhibitors compound and non-sodium dependent glucose transporter inhibitors, medicine, anti-obesity medicine, antihypertensive drug, antiplatelet drug, Antiatherosclerosis medicine and/or the hypolipidemic of treatment diabetic complication;

Wherein said sodium dependent glucose transporter inhibitors compound is to have the compound of following structure or salt or the steric isomer that it is pharmaceutically accepted:

Wherein A is CH ₂And position between with respect to glucoside being, R ¹, R ²And R ^2aRespectively be H, and R ³Be following group:

4-Me, 4-OH, 3-Me, H, 3-OMe, 4-CO ₂Me, 4-CF ₃, 4-NHAc, 4-SO ₂Me, 4-Ph, 4-NHSO ₂Ph-4 '-Me, 4-NHSO ₂Me, 4-CO ₂H, 4-thiadiazoles, 4-tetrazolium, 4-OCH ₂Ph-4 '-CN, 4-OCHF ₂, 4-sec.-propyl, 2-sec.-propyl, 4-O-n-propyl, 4-tetrazolium-2 '-Me, 4-tetrazolium-1 '-Me, 4-OPh, 4-n-propyl, 4-normal-butyl, 4-SO ₂Et, 4-SO ₂-n-propyl, 4-SO ₂Ph or 4-SOMe.

15. drug regimen, it comprises the antidiabetic medicine of sodium dependent glucose transporter inhibitors compound and non-sodium dependent glucose transporter inhibitors, medicine, anti-obesity medicine, antihypertensive drug, antiplatelet drug, Antiatherosclerosis medicine and/or the hypolipidemic of treatment diabetic complication;

Wherein said sodium dependent glucose transporter inhibitors compound is to have the compound of following structure or salt or the steric isomer that it is pharmaceutically accepted:

16. any one described drug regimen in the claim 1,14 or 15, it comprises described sodium dependent glucose transporter inhibitors compound and antidiabetic medicine.

17. the drug regimen of claim 16, wherein said antidiabetic medicine are biguanide, sulfonylurea, alpha-glucosidase inhibitors, peroxisome proliferation albumen activation receptor (PPAR) gamma agonist, peroxisome proliferation albumen activation receptor α/γ dual agonists, lipocyte fatty acid binding protein (aP2) inhibitor, DPP IV (DP4) inhibitor, euglycemic agent, glucagon-like-peptide-1 (GLP-1), Regular Insulin, meglitinide, protein-tyrosine-phosphatase 1B (PTP1B) inhibitor, in glycogen phosphorylase inhibitors and/or the grape sugar-6-inhibitors of phosphatases 1,2,3 or the medicine more than 3 kind.

18. the drug regimen of claim 17, wherein said antidiabetic medicine are N1,N1-Dimethylbiguanide, Glyburide, glimepiride, glipyride, Glipizide, P-607, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, Rosiglitazone, Regular Insulin, GI-262570, isaglitazone, JTT-501, NN-2344, YM-440, R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-H039242, KRP297, AC2993, among LY315902 and/or the NVP-DPP-728A 1,2,3 or the medicine more than 3 kind.

19. the drug regimen of claim 16, the weight ratio of wherein said sodium dependent glucose transporter inhibitors compound and antidiabetic medicine are at 0.1-300: in 1 the scope.

20. any one described drug regimen in the claim 1,14 or 15, wherein said anti-obesity medicine are β-3 2-adrenergic agonist components, lipase inhibitor, thrombotonin and dopamine reuptake inhibitor, Tiroidina beta receptor compound and/or anoretics.

21. the drug regimen of claim 20, wherein said anti-obesity medicine is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, Dextrofenfluramine, phentermine, Phenylpropanolamine and/or Mazindol.

22. any one described drug regimen in the claim 1,14 or 15, wherein said hypolipidemic are rise thing, lipoxygenase inhibitor or the acyl-CoA of microsomal triglyceride transfer protein (MTP) inhibitor, hydroxymethyl glutaryl Kiev enzyme A (HMG CoA) reductase inhibitor, inhibitor for squalene synthetic enzyme, fibric acid derivative, low-density lipoprotein (LDL) receptor active: cholesterol acyltransferase (ACAT) inhibitor.

23. being Pravastatin, lovastatin, Simvastatin, atorvastatin, Cerivastatin, fluvastatin, Buddhist nun, the drug regimen of claim 22, wherein said hypolipidemic cut down his spit of fland, visastatin, atavastatin, superstatin, fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, MD-700 and/or LY295427.

24. the drug regimen of claim 22, the weight ratio of wherein said sodium dependent glucose transporter inhibitors compound and hypolipidemic are at 0.1-300: in 1 the scope.

25. any one describedly is combined in the application of making in the medicine be used for the treatment of type ii diabetes in the claim 1,14 or 15.